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INTRODUCTION 
 
Dyspeptic symptoms are a common phenomenon that most people experience every once in a 
while. Luckily, the vast majority of these sensations are not severe enough to consult a physician 
(1,2). The term dyspepsia refers to a broad range of symptoms mainly related to pain and/or 
discomfort centred in the upper abdomen, which can, but are not necessarily, related to a meal. 
Gastric acid seems to be a major factor involved in the development of these symptoms: in many 
patients who do consult a physician, treatment with gastric acid inhibitors is successful (3-5). 
 
Unfortunately, the remaining proportion, about 30-40% [results DIAMOND study, Lancet, in press] 
of patients, does not respond sufficiently to initial acid inhibiting medication and symptoms 
persist or recur. Current guidelines for physicians prescribe treatment with a stronger/higher 
dose acid inhibitor for a longer period, or an upper gastrointestinal endoscopy if either the 
patient or the physician needs reassurance that there is no severe pathology underlying 
symptoms. About 60% of patients undergoing an endoscopy will not have any organic pathology 
that might explain their dyspeptic symptoms (6,7). These patients are diagnosed with functional 
dyspepsia. 
 
Functional dyspepsia is, after the irritable bowel syndrome (IBS), the second most prevalent 
functional gastrointestinal disorder. The term ´functional´ is used when no organic disorder can be 
identified that might explain symptoms. It represents a mishmash of symptoms that can become 
more or less severe over time, respond unsatisfactory to treatment, and are not easily described 
by the patient so it is often difficult for a physician to obtain an objective image of the 
complaints. The term itself, however, implicates that these symptoms have a ´function´; as if they 
are messengers indicating an underlying problem that should be solved. Unfortunately, despite all 
research conducted in this field, the etiology of dyspeptic symptoms has remained unclear, and 
there is no treatment available that is effective in at least a substantial proportion of patients. 
 
OUTLINE OF THE THESIS 
 
The aim of this thesis is to provide some insight in the complex mechanisms underlying the 
disorder functional dyspepsia. For this purpose, several studies were conducted regarding the 
‘functionality’ of dyspepsia: (i) attempts were made in this large pool of patients to identify 
specific characteristics that could facilitate differentiation between subjects with various 
etiological factors underlying symptoms, and (ii) the function of these symptoms in indicating 
underlying disorders was assessed.  
 
PART I: EPIDEMIOLOGY 
 
In the early nineties several studies were conducted to obtain insight in the prevalence of 
dyspeptic symptoms and to identify characteristics that differentiate consulters (patients who seek 
help from the doctor) from non-consulters. The prevalence of various organic abnormalities 
underlying symptoms, diagnosed at endoscopy was also assessed. However, these initial studies 
were often conducted in specific subpopulations, such as students or the elderly. In addition, 
there have been some significant changes that could have influenced the prevalence of 
gastrointestinal symptoms and disorders ever since: proton pump inhibitors and the eradication 
of Helicobacter pylori have been introduced in national and international guidelines for the 
treatment of patients presenting with upper abdominal symptoms. The use of NSAIDS, known 
to cause upper abdominal symptoms, has increased. The prevalence of overweight is steadily 
increasing, and lifestyle habits associated with this increase, such as smoking, diet and physical 
exercise, have altered.  
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Chapter 1 of this thesis describes a study in which a questionnaire on gastrointestinal symptoms 
was filled out by a large representative sample, in order to obtain insight in the current prevalence 
of gastrointestinal symptoms in the general population. In chapter 2 the prevalence of various 
gastrointestinal disorders, diagnosed at upper gastrointestinal endoscopy, is compared to the 
prevalence of the same disorders in the early nineties.  
 
PART II: ETIOLOGY  
 
Being the most prevalent functional gastrointestinal disorder, almost all research conducted in 
this field is aimed at IBS. Although there are substantial differences between IBS and functional 
dyspepsia, there are also a lot of similarities, and symptoms often overlap (8,9). It is therefore not 
inconceivable that there is a mutual mechanism underlying both disorders.  
 
Like in IBS, it was previously shown that patients with functional dyspepsia have more mental 
distress in comparison to healthy controls. In chapter 3 of this thesis the levels of anxiety and 
depression are compared between patients with an organic disorder underlying symptoms and 
patients with functional dyspepsia. Furthermore, genetic studies previously identified several 
candidate genes involved in symptom generation in functional gastrointestinal disorders. In 
chapter 4 of this thesis one of these functional polymorphisms, encoding for the serotonin 
transporter protein, is investigated through meta-analysis of all published data on the association 
between this polymorphism and IBS.  
 
PART III: DIAGNOSIS 
 
In patients that consult a physician, attempts have been made to identify subgroups beforehand 
that would be more likely to have a common underlying disorder, or a better response to certain 
treatments. General practitioners use specific criteria to determine which patients should be 
referred for endoscopic investigation. In chapter 5 the association between these referral 
indications and endoscopic outcomes is assessed. Furthermore, chapter 6 of this thesis describes 
the association between alexithymia, a character trait where a person has difficulty to distinguish 
between emotions and bodily sensations, and the risk for having an organic disorder at upper 
gastrointestinal endoscopy.  
 
If organic disorders have been excluded, functional dyspepsia is diagnosed. Symptoms-based 
classification systems have been proposed in order to facilitate a positive diagnosis of functional 
dyspepsia, rather than diagnosis by exclusion. In chapter 7 data of a large sample of patients who 
underwent endoscopy, and were diagnosed with functional dyspepsia, are analyzed in order to 
assess the applicability of these symptoms-based classification systems.  
 
PART IV: TREATMENT 
 
About 90% of patients with functional dyspepsia is treated by the general practitioner. If acid-
inhibiting therapy fails to relief symptoms, upper gastrointestinal endoscopy is often performed 
because it is considered that a negative endoscopic examination has a positive effect in providing 
reassurance that there is no severe pathology underlying symptoms. Chapter 8 describes a study 
in which anxiety and depression scores were used as a proxy for psychological well-being. This 
way the reassuring effect of endoscopy was assessed.  
 
Because the current assumption is that symptoms of functional dyspepsia are a manifestation of a 
complex interplay of disturbed gut functioning and psychological responses, several studies have 
investigated the effect of antidepressants. Results were contradicting, though predominantly 
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positive, and the quality of trials poor. Chapter 9 describes a randomized placebo controlled trial 
investigating the effect of a selective serotonin and norepinephrine reuptake inhibitor, 
venlafaxine, in patients with functional dyspepsia.  
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GASTROINTESTINAL SYMPTOMS ARE STILL COMMON IN A 
GENERAL WESTERN POPULATION. 
 
 
Lieke A.S. van Kerkhoven, Ties Eikendal, Robert J.F. Laheij, Martijn G.H. van Oijen, Jan B.M.J. 
Jansen. 
 
Netherlands Journal of Medicine 2008;66:18-22 
 
 
 
 
 
 
 
 
 
Background: Results from studies conducted in the late eighties and early nineties showed that 
gastrointestinal symptoms were common among the general population. Meanwhile, lifestyle 
habits have changed and important treatment options have been introduced. This might have 
influenced symptom prevalence.  
Methods: This study aimed to describe the current prevalence of upper and lower gastrointestinal 
symptoms within the general population. For this purpose, a demographically representative 
sample of the Dutch population within the city of Nijmegen and surrounding areas was selected 
after careful comparison with demographic figures from a government demographic database. 
Participants were invited to fill out a valid self-report questionnaire about gastrointestinal 
symptoms and prevalence figures were calculated.  
Results: A total of 5000 questionnaires was sent and 1616 (32%) were returned. Of these, 839 
(52%) subjects reported to have had upper (43%) or lower (38%) gastrointestinal symptoms in 
the past 4 weeks. The most prevalent individual symptoms reported, were: flatulence (47%), 
abdominal rumbling (40%), bloating (37%), alternating solid and loose stools (31%), belching 
(25%) and postprandial fullness (25%). People who smoked or used a protonpump inhibitor had 
an increased risk for reporting both upper as well as lower gastrointestinal symptoms (OR 1.99; 
95%CI=1.56-2.55, and OR 1.37; 95%CI=1.01-1.75, respectively for smoking; and OR 3.17; 
95%CI=2.17-4.72, and OR 2.14; 95%CI=1.49-3.08, respectively for PPIs). 
Conclusion: Both upper as well as lower gastrointestinal symptoms are very common in a 
representative sample of a general Western population.  
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INTRODUCTION 
 
Gastrointestinal symptoms are very common in the general population and a frequent reason for 
consultation of a healthcare professional (1). In 1989, it was shown that 38 percent of an English 
population reported dyspeptic symptoms (2). When this study was expanded over five other 
regions in England and Scotland, the six-month period prevalence of dyspepsia was 41 percent 
(3). In another random sample of elder (65-93 years of age) Minnesota inhabitants, studied in 
1992, similar results were obtained (4). In addition, a prevalence ranging from 10-25% was 
observed of lower abdominal symptoms, such as constipation and diarrhoea.  
 
No recent data on the prevalence of gastrointestinal symptoms in a general population are 
available. Since these studies were conducted, there have been significant changes in lifestyle 
habits, treatment options, and socio-economical and cultural factors, influencing upper and lower 
gastrointestinal symptoms. The most prominent changes were probably the introduction of 
protonpump inhibitors and strategies to eradicate of Helicobacter pylori in national and international 
guidelines for the treatment of patients with upper gastrointestinal symptoms. Subsequently, 
infection rates of H. pylori have decreased, whereas the number of prescriptions for PPIs have 
increased dramatically (5,6). Secondly, usage of gastro-toxic drugs, such as NSAIDs, has 
increased and gastrointestinal symptoms induced by these drugs are rising (7). Thirdly, the 
prevalence of overweight and obesity are increasing. A high body mass index, and the lifestyle 
habits that precede that, are associated with the development of both upper as well as lower 
gastrointestinal symptoms, such as regurgitation, gastro-oesophageal reflux and altered bowel 
movements (8).  
 
These developments strengthened the need for data on the current prevalence of gastrointestinal 
symptoms in the general population. Indeed, a more recent study has shown that, although there 
is great inter-country variability (46% in Mexico – 10% in Japan), abdominal cramping and pain 
are still common in a general population (9). Similar results were obtained in the Kalixanda study 
from Northern Sweden, in which the three-month period prevalence of predominantly reflux 
symptoms was found to be about 40% (10,11).  
 
Although both studies indicate that upper gastrointestinal symptoms are still a frequent 
phenomenon among the general population, they were conducted in specific populations and 
investigated specific symptom complexes. This study aims to investigate the prevalence of a 
broad range of both upper as well as lower gastrointestinal symptoms in a representative sample 
of the general population. 
 
PATIENTS AND METHODS 
 
SUBJECTS 
 
Questionnaires were spread door-to-door in the city of Nijmegen and the Nijmegen area. Data 
from Statistics Netherlands (CBS) were used to select neighborhoods that matched the general 
Dutch population for social economic status, age, property value, racial configuration and 
household configuration. One person, over the age of 18, per household was asked to fill out the 
questionnaire and to return it by mail. It was specifically mentioned that the questionnaire should 
also be filled out if gastrointestinal symptoms were absent. 
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QUESTIONNAIRE 
 
The questionnaire contained items on demographics, lifestyle habits and current medication use. 
Severity of gastrointestinal symptoms in the past 4 weeks was assessed using a valid self-report 
questionnaire. This questionnaire has been extensively used before (12-15) and symptoms 
include: upper abdominal pain, epigastric pain, heartburn, regurgitation, abdominal rumbling, 
bloating, nausea, empty feeling in the stomach, early satiety, postprandial fullness, belching, 
flatulence, haematemesis, dysphagia, questions on defecation and foetor ex ore. Subjects were 
asked to rate the severity of gastrointestinal symptoms on a 7-point Likert scale (0=absent; 
1=hardly any; 2=mild; 3=moderate; 4=moderately severe; 5=severe and 6=very severe). In 
analysis a score of 2 or higher was defined as symptom presence. Questionnaires returned 
without any of the questions filled out were not taken into further analysis. 
 
STATISTICAL ANALYSIS 
 
Statistical analysis was performed using SAS statistical software (version 8.2). Data on symptom 
frequencies were summarized using descriptive statistics. Participants reporting three or more of 
the following symptoms: epigastric pain, heartburn, regurgitation, abdominal rumbling, bloating, 
empty feeling, nausea, vomiting, early satiety, postprandial fullness, belching, haematemesis, 
dysphagia and foetor ex ore, were defined as having upper gastrointestinal symptoms. Having 
three or more of the other symptoms was defined as having lower gastrointestinal symptoms. 
Alcohol abuse was defined as drinking ≥14 units/week for women and ≥21 units/week for men 
(National Drug Monitor Netherlands / Trimbos institute), and excessive coffee consumption was 
defined as the consumption of ≥6 units/day (16). Any consumption of cigarettes or cigars was 
defined as current smoking. Body Mass Index (BMI) was calculated as the weight in kilograms 
divided by the square of the height in meters (kg/m2), classifications were made according to 
WHO standards: a BMI ≤18.5=underweight, a BMI 18.5-25=normal and a BMI ≥25=overweight 
(17). Comparison of symptom frequencies between genders was done using Pearson’s chi-square 
analysis, and Pearson’s correlation coefficient was calculated to assess the correlation between age 
and number of symptoms. To adjust for multiple testing, a p-value < 0.01 was considered 
statistically significant. Logistic regression analysis was used to assess adjusted odds ratio’s in 
order to identify risk factors for upper or lower gastrointestinal symptoms. 
 
RESULTS 
 
A total of 5000 questionnaires was 
spread and 1616 were returned (32%) 
(table 1) 
 
Eighty percent of all subjects reported 
to have had at least one 
gastrointestinal symptom in the past 4 
weeks. The most frequently reported 
upper gastrointestinal symptoms were: 
bloating (37%), belching (25%), 
postprandial fullness (25%) and 
heartburn (21%). Lower 
gastrointestinal symptoms most 
frequently reported were: flatulence 
(47%), abdominal rumbling (40%),  
alternating solid and loose faeces (31%) and strong urgency (24%) (Figures 1 and 2). 
Table 1: population demographics (N = 1616) 
Mean age ±SD 52.3 ± 17.2 
Male gender N(%) 549 (34%) 
Non–Western European origin N(%) 104 (6.4) 
BMI N(%)  <18.5 33 (2.0) 
(18.5-25) 814 (50.4) 
≥25 704 (43.6) 
Smoking N(%) 385 (24.0) 
Alcohol abuse N(%) 102 (6.3) 
Excessive coffee consumption N(%) 383 (23.7) 
Current medication N(%)  
Protonpump inhibitor 134 (8) 
Aspirin 165 (10) 
Histamine-2 receptor antagonist 17 (1) 
NSAID 66 (4) 
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Figure 1: Prevalence of upper gastrointestinal symptoms. 
0% 10% 20% 30% 40%
Foetor ex ore
Solid foods
Liquid food
Dysphagia
Haematemesis
Belching
Postprandial fullness
Early satiety
Vomiting
Nausea
Empty feeling
Bloating
Regurgitation
Heartburn
At night/asleep
During daytime
In general
Epigastric pain
 
Figure 2: Prevalence of lower gastrointestinal symptoms. 
0% 10% 20% 30% 40% 50% 60%
Steatorrhoea
Incomplete
Strong urgency
Frequently with pain
Constipation
Alternately solid or loose
Diarrhea
Frequently hard
Mucous
Bloody
Melaena
Abnormal defecation
Flatulence
No decline after defaecation
After fasting
Postprandial
In general
Abdominal pain
Abdominal rumbling
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Women statistically significantly more often reported abdominal pain in general (27% vs. 16%), 
abdominal rumbling (42% vs. 35%), bloating (41% vs. 30%), nausea (20% vs. 9%), early satiety 
(15% vs. 9%), postprandial fullness (27% vs. 20%), constipation (7% vs. 18%) and defecation 
frequently with pain (13% vs. 7%) than men (all p-values <0.01). 
 
In general, 43% of participants reported to have had at least 3 upper gastrointestinal symptoms in 
the past four weeks and 38% reported to have had at least 3 lower gastrointestinal symptoms. 
Although proportions of subjects with upper and lower gastrointestinal symptoms seemed to 
decrease with increasing age in both men as well as women (figure 3), no correlation could be 
shown (r=-0.22 in men, and r=-0.21 in women for age and upper abdominal symptoms; r=-0.19 
in men, and r=-0.24 in women for age and lower abdominal symptoms; all p-values <0.01).  
 
figure 3: Prevalence of upper and lower gastrointestinal symptoms in men and women with 
increasing age. 
18 - 29 yr 30 - 39 yr 40 - 49 yr 50 - 59 yr 60> yr
%
0
10
20
30
40
50
60
70
Women with upper gastrointestinal symptoms
Men with upper gastrointestinal symptoms
Women with lower gastrointestinal symptoms
Men with lower gastrointestinal symptoms
 
 
Of all subjects using either a PPI or a H2-receptor antagonist, 68% reported upper 
gastrointestinal symptoms and 55% reported lower gastrointestinal symptoms. Smoking and 
protonpump inhibitor use were associated with an increased risk for both upper as well as lower 
gastrointestinal symptoms (OR 1.99; 95%CI=1.56-2.55, and OR 1.37; 95%CI=1.01-1.75, 
respectively for smoking; and OR 3.17; 95%CI=2.17-4.72, and OR 2.14; 95%CI=1.49-3.08, 
respectively for protonpump inhibitors). Excessive coffee consumption was associated with a 
decreased risk for upper and lower gastrointestinal symptoms (OR 0.75; 95%CI=0.59-0.96, and 
OR 0.72; 95%CI=0.56-0.93, respectively).  
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DISCUSSION 
 
The results of this large-sample study show that upper and lower gastrointestinal symptoms are 
very common in a general Western population. The vast majority of subjects experienced at least 
one gastrointestinal symptom in the past four weeks. Women reported more symptoms than 
men, and the number of symptoms seems to decrease with increasing age, regardless of gender. 
Smoking and usage of protonpump inhibitors were associated with the presence of 
gastrointestinal symptoms, and there was a negative association with excessive coffee 
consumption. 
 
Other studies investigated the prevalence of dyspeptic and irritable bowel syndrome-related 
symptoms before. These studies, performed since 1951, reported a prevalence ranging from 25% 
up to 40%, depending on study population and symptom definition (2,18-21). Since these first 
data, several changes in factors associated with the treatment and development of gastrointestinal 
symptoms have taken place, such as altered treatment options, increasing bodyweight and altered 
life-style habits. It might be expected that this has influenced gastrointestinal symptom etiology 
and, with that, prevalence. Indeed, in a recent study we showed that the prevalence of upper 
gastrointestinal disorders found at endoscopy changed significantly over time compared to 15 
years ago (22). Unfortunately, the current data do not allow us to draw any conclusions on 
diagnoses, and there is no data available on these symptoms in a comparable population. 
Nevertheless, proportions of patients with symptoms are in concordance with proportions 
described in the earlier studies, and although etiology and the prevalence of certain disorders may 
have changed, gastrointestinal symptoms are still a common phenomenon in the general 
population.  
 
Protonpump inhibitors and smoking were associated with an increased risk for both upper as 
well as lower gastrointestinal symptoms. Smoking has previously been associated with the 
development of gastrointestinal disorders (23,24), and our results show once again how 
important it is for healthcare workers to emphasize the importance of quitting for the prevention 
and salvation of symptoms. Protonpump inhibitors are currently among the most frequently 
prescribed drugs in The Netherlands and numbers are still increasing (source: GIP databank; 01-
05-2007). Currently, a common approach in western countries is to prescribe acid-suppressive 
drugs for upper gastrointestinal tract symptoms without suspicion of a malignancy (25). A large 
part of patients with upper gastrointestinal symptoms has no acid-related disorder underlying 
symptoms and it is therefore likely that a proportion is using acid-inhibiting medication without 
the expected effect on gastrointestinal symptoms (26). It is very probable that the observed 
increased risk is a reflection of the large amount of people using this medication without 
obtaining the desired effect, rather than a true association between the use of PPIs and symptom 
development. The association with lower gastrointestinal symptoms might be the result of 
common side effects of protonpump inhibitors on the lower gastrointestinal tract, such as 
diarrhea, constipation and flatulence (27). On the other hand, it is known that gastrointestinal 
symptoms are often hard to locate, and that upper and lower gastrointestinal symptoms often 
coexist (28). It is very well possible that many patients received a protonpump inhibitor for their 
upper gastrointestinal symptoms, while their lower gastrointestinal symptoms persisted. 
Regarding the inversed association with excessive coffee consumption: it is imaginable that 
subjects with gastrointestinal symptoms consume less coffee in order to avoid symptoms, rather 
than that coffee itself has a protective effect for symptom development.  
 
The response rate to the self-report questionnaire was rather low, compared to the previously 
mentioned studies investigating symptom prevalence. The low response rate is most probably 
due to the voluntary, anonymous nature of this study: questionnaires were spread door-to-door, 
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whereas other studies often used a clinical or outpatient setting to approach potential 
participants. This last method leads to higher response rates since people are more likely to fill 
out a questionnaire if asked to by a healthcare worker. Our purpose was to obtain insight in a 
general population, regardless of medical background or health care seeking behavior. Therefore, 
response was dependent of individual willingness to fill out the questionnaire, and response bias 
might have influenced our results. The investigated sample matched the general Dutch 
population for several demographic and socio-economic factors (data from Statistics Netherlands 
(CBS)). However, mean age of the responders was slightly higher, and there were more women 
than men. This would mean that our results could in fact represent an underestimation of 
prevalence because younger people report more symptoms, or that the higher proportion of 
women has caused an overestimation because women tend to report more symptoms. The truth 
lies probably somewhere in the middle; considering these contradicting influences on symptoms, 
the large sample size and the resemblance of our sample with the general Dutch population for 
other factors, it might be assumed that data about the prevalence of symptoms are representative 
for the general population as well.  
 
In summary, over the past decades, several changes in factors associated with the development 
and treatment of gastrointestinal disorders have taken place. The results of this study show that, 
although these changes might have altered the etiology and prevalence of underlying disorders, 
gastrointestinal symptoms are still very common in the general population.  
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Background/Aim: Over the past 15 years, there were considerable changes in factors associated 
with the development and treatment of upper gastrointestinal symptoms, of which the 
introduction of protonpump inhibitors and Helicobacter pylori eradication in guidelines for 
treatment of patients with dyspepsia are the most prominent: findings at open-access upper 
gastrointestinal endoscopy have not been evaluated properly ever since. This study aims to 
compare the current prevalence of upper gastrointestinal endoscopic findings to the prevalence 
15 years ago.  
Methods: Data about endoscopic findings of consecutive patients for the first time referred for 
open-access upper gastrointestinal endoscopy between January 2002 and December 2004 was 
collected from medical files. The prevalence of each specific finding was compared with data 
described in three historical populations about 15 years ago. 
Results: The current and historical study population consisted of 1,286 and 3,062 subjects, 
respectively. The prevalence of peptic ulcer disease and duodenitis significantly decreased by 
12,6% (95%CI: 14,5-10,7) and 2,9% (95%CI: 4,5-1,3), respectively. On the other hand, the 
prevalence of reflux-oesophagitis and Barrett’s oesophagus both significantly increased by 6,9% 
(95%CI: 4,2-9,6) and 2,1% (95%CI: 0,8-4,4), respectively. 
Conclusions: Compared to 15 years ago, the prevalence of specific findings at open-access upper 
gastrointestinal endoscopy has changed considerably. 
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INTRODUCTION 
 
During the late eighties open-access upper gastrointestinal (GI) endoscopy was introduced in The 
Netherlands, providing general physicians with the possibility to refer patients with GI symptoms 
directly for an endoscopy. Back then, several studies have evaluated findings at these 
endoscopies, in order to obtain insight in the prevalence of various disorders of the proximal GI 
tract (1-3).  
 
Meanwhile, there have been significant changes in lifestyle habits, endoscopic techniques, and 
socio-economical and cultural factors, influencing upper gastrointestinal symptoms. The most 
prominent changes, however, were probably the introduction of the test-and-treat strategy for 
Helicobacter pylori infection in many national and international guidelines for patients presenting 
with upper abdominal symptoms, in order to suppress peptic ulcer disease. Furthermore, proton 
pump inhibitors (PPI) have become increasingly popular for treatment of acid-related disorders, 
such as GERD and peptic ulcer disease, and they are often co-prescribed with NSAIDs because 
these drugs are known to cause gastric mucosal damage (4). Between 1991 and 1998 the number 
of prescriptions in The Netherlands for PPIs increased from 214,000/year to almost 2 
million/year, which is a mean increase of 37% annually, while the number of prescriptions for 
other acid suppressive drugs, such as H2-receptor antagonists and antacids, remained quite stable 
over the years.  
 
It is generally accepted that treatment with PPIs and eradication of H. pylori are very effective in 
curing and preventing acid-related disorders. On the other hand, factors associated with the 
development of upper gastrointestinal disorders, such as the increased usage of NSAIDs, the 
increased prevalence of overweight and dietary changes, might have caused the prevalence of 
certain disorders to increase. Limited data is available about the influence all these factors had on 
the prevalence of findings at open-access upper GI endoscopy. Therefore the aim of this study 
was to compare the current prevalence of specific endoscopic findings to the prevalence about 15 
years ago.  
 
MATERIALS AND METHODS 
 
CURRENT POPULATION 
 
Information about current endoscopic findings was obtained from medical files of patients 
referred for open-access upper GI endoscopy to the Canisius-Wilhelmina Hospital in Nijmegen, 
The Netherlands, between February 2001 and February 2004. This is a large district general 
hospital. All patients were referred according to Dutch guidelines for general practitioners 
regarding the management of patients with upper abdominal symptoms. These guidelines state 
that an endoscopy is indicated if alarm symptoms are present, when the general practitioner 
needs reassurance that there is no serious pathology underlying symptoms or if symptoms recur 
or persist after empirical treatment with a protonpump inhibitor and Helicobacter Pylori eradication.  
 
Patients were divided according to endoscopic finding: i.e. gastroesophageal carcinoma, Barrett’s 
oesophagus, reflux oesophagitis, gastric/duodenal ulcer, or duodenitis/bulbitis. It was possible 
for patients to have multiple endoscopic findings. To prevent inclusion of patients referred for a 
follow-up endoscopy, only patients who had no endoscopy in the preceding 6 months were 
included. 
 
  21
HISTORICAL POPULATION 
 
Data about the prevalence of endoscopic findings about 15 years ago were obtained from 
published data, describing three historical populations from different areas surrounding 
Nijmegen in The Netherlands: The first was described by Numans et al. They included patients 
referred for the first time for an open-access upper GI endoscopy between October 1986 and 
1988 (5). The second study was by Schaap et al., who described findings in patients referred for a 
first upper GI endoscopy in 1990 (6), and the third study was performed by Adang et al. in 
patients who were also referred for a first upper GI endoscopy between January 1989 and 
October 1990 (3). 
 
All three studies reported data on endoscopic findings, and described carcinoma, reflux 
oesophagitis, gastric/duodenal ulcer, duodenotis/bulbitis. Only the group of Numans also 
reported Barrett’s oesophagus, but not duodenitis. 
 
STATISTICAL ANALYSIS 
 
Statistical analysis was undertaken with SAS statistical software, version 8.0. Data were analysed 
by means of frequency tables and descriptive statistics. The three historical populations were 
pooled to one large population, and weighted means were calculated, according to the sizes of the 
individual samples. To compare the prevalence of specific disorders in the historical population 
to the current population, differences were calculated with a 95% confidence interval. When 0 
was not included in the confidence interval, a statistically significant difference was assumed. 
 
RESULTS 
 
The historical populations described by Numans, Adang, and Schaap included 861, 1205 and 996 
patients respectively. Together, they consisted of a total of 3062 patients, with a mean (±SD) age 
of 50 ±15 years and 57% was male. In the current population, 1286 patients were included with a 
mean (±SD) age of 54 ±15 years and 49% was male (difference age: 4 ±0.98 years; gender: 8%; 
p<0,01).  
 
Comparing the prevalence of the specific disorders in the historical population with the 
prevalence in the current population (Table 1), the most pronounced difference is observed in 
peptic ulcer disease; a statistically significant decrease from 18.0% to 5.4%, a difference of 12.6% 
(95%CI: 10.7-14.5). Duodenal ulcer decreased more than gastric ulcer; 9.4% (95%CI: 7.9-10.9) 
and 3,0% (95%CI: 4.3-1.7), respectively. Duodenotis/bulbitis has also become less frequent as 
well during the past 15 years: from 8.3% to 5.4%, a decrease of 2.9% (95%CI: 1.3-4.5). 
 
On the other hand, reflux oesophagitis has become more prevalent compared with 15 years ago: 
an increase of 6.9% (95%CI: 4.2-9.6). Comparing the current prevalence with the prevalence 
described by Numans et al., there is a slight increase of Barrett’s oesophagus as well: from 2.6% 
to 4.7%, a difference of 2.1% (95%CI: 0.8-4.4).  
 
Gastric and oesophageal cancer have remained just as prevalent as 15 years ago: 2.0% vs 1.8%; a 
difference of 0.2% (95%CI: -1.1-0.7).  
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Table 1: Comparison of the prevalence of various disorders of the proximal GI tract between 
the historical and current population. 
 Historical population
N (%) 
Current population 
N (%) Difference** (95% CI)
Cancer 60 (2,0) 23 (1,8) 0,2 (-1,1 _ 0,7) 
Esophageal 15 (0,5) 11 (0,9) 0,4 (-0,2 _ 1,0) 
Gastric 45 (1,5) 12 (0,9) 0,6 (-1,3 _ 0,1) 
Barrett’s esophagus 22 (2,6) 60 (4,7) 2,1 (0,8 _ 4,4) 
Reflux-esophagitis 462 (15,1) 283 (22,0) 6,9 (4,2 _ 9,6) 
PUD* 551 (18,0) 70 (5,4) 12,6 (14,5 _ 10,7) 
Ventricular 177 (5,9) 37 (2,9) 3,0 (4,3 _ 1,7) 
Duodenal 374 (12,2) 36 (2,8) 9,4 (10,9 _ 7,9) 
Duodenitis/bulbitis 255 (8,3) 70 (5,4) 2,9 (4,5 _ 1,3) 
* PUD Peptic Ulcer Disease. ** If the 95% confidence interval does not include 0, there is a 
statistically significant difference. 
 
DISCUSSION 
 
The prevalence of various disorders of the proximal gastrointestinal (GI) tract as observed in the 
current population are in concordance with observations in other recent studies (7). We have 
compared the current prevalence of these disorders with the prevalence of the same disorders 
about 15 years ago. During this period there were significant changes in factors associated with 
the development and treatment of these disorders. Most importantly, empirical treatment with 
proton pump inhibitors and the eradication of Helicobacter pylori were introduced in guidelines for 
the treatment of patients with upper abdominal symptoms. On the other hand, the prevalence of 
overweight and usage of NSAIDs have increased, and endoscopic techniques have been 
extensively developed. Our results show that these developments have contributed to the 
decrease in the prevalence of peptic ulcer disease and duodenitis, and that reflux oesophagitis has 
become more prevalent than 15 years ago. 
 
Overweight and obesity have been associated with the development of reflux oesophagitis (8-11). 
In The Netherlands, the number of people with overweight (BMI>25), or obesity has increased 
over the past years: in 1987/88, 28% of the adult Dutch population was overweight, while 
currently 40% is overweight and about 10% is obese (BMI>30) (12). This dramatic increase 
might explain a large part of the observed increase in oesophagitis. Furthermore, infection with 
H. Pylori is thought to be relatively protective for the occurrence of reflux oesophagitis (13,14). 
The most plausible explanation for this is that H. Pylori causes chronic gastritis, which leads to 
gastric atrophy and hypochlorhydria. H. Pylori eradication could therefore explain part of the 
increase in the prevalence of reflux oesophagitis as hypochlorhydria subsides. Although it has 
been described that among patients without an H. pylori infection reflux oesophagitis is more 
common (15), evidence is inconclusive and contradicting results have been reported on whether 
eradication itself could cause reflux oesophagitis (16-19). More studies are required to investigate 
the true association between infection with H. pylori and oesophagitis. Finally, endoscopic 
techniques have also developed over the last decade. Although most important disorders were 
probably already correctly visible in the past, it is fair to assume that the better vision of the 
current endoscopes caused a higher diagnostic yield. For the results of this study this implicates 
that the observed decrease in PUD and duodenitis is in fact even larger, while the increases in 
reflux oesophagitis and Barrett’s oesophagus are actually overestimated. Finally, the increase in 
the prevalence of reflux oesphagitis and Barrett’s oesophagus can partly be explained by an 
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increased awareness of these conditions among endoscopists. If this is case, the observed 
increase would in fact be an overestimation. 
 
Only one of three historical populations described Barrett’s oesophagus, and a statistically 
significant increase in its prevalence was observed. This is in accordance with the results of a 
large database study (N=500.000) recently published by Soest et al (20). This might be due to the 
increased awareness mentioned earlier, but it might just as well be the result of the increase of 
reflux oesophagitis, which is a notorious risk factor for the development of Barrett’s oesophagus.  
 
Unfortunately we did not have the original data of the three historical populations at our 
disposal; all information was obtained from published articles. Therefore, it was not possible to 
assess the influence of regional variables, such as smoking, diet and NSAID use. However, by 
combining 3 regional populations to a very large one, we deduce that this large group is 
representative of the general Dutch population in the beginning of the nineties. Furthermore, 
differences in definitions of disorders are not to be excluded, although this is not very probable 
because definitions of macroscopic disorders are largely standardized. At last, since endoscopic 
findings may be masked by prior treatment, patients in The Netherlands are instructed to 
discontinue acid suppressive medication 2 weeks prior to endoscopy. This period is insufficient 
to allow for all ulcers and oesophagitis to relapse. It is also possible that a small proportion of 
patients did not discontinue their medication during endoscopy, which masked organic 
abnormalities. This means that the decrease in the prevalence of peptic ulcer disease and 
duodenitis can be an overestimation, while the increase in reflux esophagitis would in fact be 
even more pronounced.  
 
The historical population contained more men, and was younger than the current population. 
Increasing age and male sex are both associated with a higher risk for major findings at upper GI 
endoscopy (21,22). It is possible that these differences between the two populations have 
influences results. It is, however, hard to speculate about the effect of these differences, since it is 
unknown whether the effect of one of the two variables on endoscopic findings is larger than 
that of the other. 
 
In conclusion, during the past 15 years, there were significant changes in factors associated with 
the development and treatment of upper gastrointestinal symptoms, of which the introduction of 
PPIs and eradication of H. pylori in guidelines for the treatment of patients with upper GI 
symptoms were probably the most prominent. Evaluation of endoscopic findings after this 
period has shown that the prevalence of peptic ulcer disease and duodenitis have decreased 
considerably, implicating that these treatment strategies have fulfilled expectancies. On the other 
hand, the prevalence of reflux-oesophagitis has increased. This is probably due to the growing 
number of people with overweight, and the alterations in lifestyle habits underlying this 
increasing bodyweight, and to a lesser extent to eradication of H. pylori.  
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Background & Aim: Limited information is available about anxiety, depression and psychotropic 
medication use in patients referred for gastrointestinal endoscopy. Therefore the aim of this 
study is to determine anxiety and depression and its association with endoscopic findings in a 
representative sample of patients with persistent gastrointestinal symptoms prior to endoscopy.  
Methods: Patients referred to the hospital for endoscopy between February 2002 and February 
2004 were asked to score anxiety and depression on the Hospital Anxiety and Depression Scale 
two weeks prior to endoscopy. Information about endoscopic diagnoses was obtained from 
medical files. 
Results: A total of 1298 subjects was studied (600 upper GI endoscopies and 698 lower GI 
endoscopies). Patients referred for upper GI endoscopy used most psychotropic agents (24%; 
OR=3.1; 95%CI=2.3-4.2), especially patients with an organic abnormality when compared to 
patients without an organic abnormality (42% vs. 8%; OR=8.6; 95%CI=5.4-14.0). Patients with 
colonic polyps were more anxious (OR=1.7; 95%CI=1.0-2.9) and depressed (OR=1.8; 
95%CI=1.1-3.1) than other patients referred for lower GI endoscopy.  
Conclusions: There is no difference in anxiety nor depression between patients with and without 
organic abnormalities at endoscopy. Patients with colonic polyps are more anxious and depressed 
than other patients referred for lower GI endoscopy. Psychotropic medication use is highest 
among patients with an organic abnormality in the proximal GI tract. 
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INTRODUCTION 
 
In the majority of patients with gastrointestinal (GI) symptoms (40-80%), no pathological cause 
for their symptoms can be found (1,2). In search for an explanation for these symptoms, 
extensive research has been performed including psychological factors. Talley et al, among 
others, concluded that patients with functional dyspepsia (FD) or irritable bowel syndrome (IBS) 
who present for medical care tend to be more anxious and depressed than healthy controls (3-9). 
This also seems to be the case in subjects with functional GI symptoms who do not seek medical 
care (10-13).  
 
Little information is available about anxiety and depression in patients in whom an organic cause 
for their symptoms has been found. Patients with duodenal ulcer had significantly lower levels of 
anxiety, general psychopathology, depression, a higher general level of functioning and less 
somatic complaints from different organ systems than patients with functional dyspepsia (14,15). 
Pace and colleagues recently found no difference in general psychological distress between 
patients diagnosed with IBS or inflammatory bowel disease (16). Yet, their study contained a 
limited number of patients and with the psychological questionnaire that was used, only the 
average severity of general psychological symptoms can be calculated but not specific scores for 
anxiety or depression.  
 
The aim of this study was to determine the prevalence of anxiety and depression and its 
association with endoscopic findings in a representative sample of patients with upper or lower 
GI symptoms. In addition frequency of psychotropic medication use will be assessed. 
 
MATERIALS AND METHODS 
 
SUBJECTS 
 
Between February 2002 and February 2004, consecutive patients referred for upper or lower 
endoscopy to the Canisius-Wilhelmina Hospital in Nijmegen, The Netherlands, were asked to fill 
out a questionnaire 2 weeks prior to endoscopy. This is a general primary care district hospital. 
The questionnaire included enquiries on demographic information, alcohol and medication use, 
the presence and severity of upper and lower GI symptoms, anxiety and depression. Information 
about the endoscopy and histological findings were collected from medical files after completion 
of the questionnaire. All data were processed with Teleform automatic scanning software version 
6.0 (Cardiff Software). All aspects of the protocol were approved by the Medical Ethical 
Committees of University Medical Center St Radboud and the Canisius-Wilhelmina Hospital 
both in Nijmegen, The Netherlands. For this study, data was used of patients who had no GI 
endoscopy in the last 6 six months before enrollment. 
 
ANXIETY AND DEPRESSION 
 
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS). This is a self-completed questionnaire that has been validated and can be used in a 
variety of clinical settings (17-19). It consists of 14 items and is divided into an anxiety and a 
depression sub-scale, each comprising 7 questions rated on a scale ranging 0 to 3, depending on 
the severity of the problem described in the question. This way utilities can be calculated that 
indicate the individuals degree of anxiety or depression. A sub-scale score below 7 is considered 
normal, i.e. no signs of anxiety or depression (20). A score of 7 to 21 was considered indicative 
for (mild) depression, although clinical signs might have been absent. Questions that were not 
filled out properly were not taken into further analysis and therefore incomplete subscales were 
excluded from analysis.  
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ENDOSCOPY 
 
Patients underwent a routine diagnostic upper or lower GI endoscopy. Outcomes were entered 
into a database. If necessary, histological data were obtained from biopsies taken during 
endoscopy. These biopsies were analyzed by an experienced pathologist and results were entered 
into the same database. Results were extracted from that database and patients were divided into 
groups according to their most prominent endoscopic outcome. Patients were defined as having 
an organic disorder if their diagnosis was carcinoma, gastric or duodenal ulcer, reflux 
oesophagitis, hiatic hernia. colitis, polyps or diverticula’s. When no endoscopic or histological 
explanation for symptoms could be found, they were defined as functional. Patients who 
underwent an endoscopy in the past six months before enrollment were excluded from further 
analysis. 
 
MEDICATION 
 
Most patients included in the study used medication. Information on the use of psychotropic 
agents was obtained from the questionnaires and taken into further analysis (TCA’s, SSRI’s, other 
non-tricyclic agents and benzodiazepines).  
 
STATISTICAL ANALYSIS 
 
Statistical analysis was undertaken with SAS statistical software, version 8.0. Data at baseline were 
analyzed by means of frequency tables and descriptive statistics. Patients with incomplete data 
were excluded from further analysis. Logistic regression analyses were performed to determine 
the odds ratios for anxiety and depression among disorders of the same part of the GI tract. 
Outcomes were adjusted for gender, age and psychotropic medication use. The latter was 
dichotomized into use and non-use. The same analyses were performed to determine odds ratios 
for medication use. Results were adjusted for age and gender. Overall, an alpha <0.05 was 
considered statistically significant. 
 
RESULTS 
 
Overall, 1969 out of the 3615 (54%) questionnaires that were sent were returned. Of these, 671 
were excluded from further analysis as a result of improperly filled out questionnaires, or a recent 
GI endoscopy. Mean age was 55 years (SD ±15). Six hundred patients underwent an upper 
gastrointestinal (GI) endoscopy and 698 a lower GI endoscopy. Previous diagnostic intervention 
(i.e. endoscopy, X-ray or Helicobacter Pylori-test) was reported by a total of 731 patients. Patients 
referred for lower GI endoscopy reported more previous endoscopic procedures (42%) than 
patients referred for upper GI endoscopy (33%), (p<0.01) (Table 1). 
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Table 1. Demographics and endoscopic findings.  
Characteristics No. of patients (%) 
Age (years)  
18 – 50  444 (34) 
> 50  854 (66) 
Gender   
Male 614 (47) 
Female 684 (53) 
Upper GI endoscopy 600 (46) 
Organic upper GI disease 280 (47) 
Functional upper GI disease 320 (53) 
Lower GI endoscopy 698 (54) 
Organic lower GI disease 133 (19) 
Functional lower GI disease 565 (81) 
Previous endoscopy 493 (38) 
Other previous diagnostic interventions* 238 (18) 
* X-ray or Helicobacter pylori test  
 
In the total study population, mild to severe anxiety was reported by 29% and mild to severe 
depression by 26% (Figure 1). Use of psychotropic agents was higher among patients referred for 
upper GI endoscopy than among patients referred for lower GI endoscopy (24% vs. 9%; 
OR=3.1; 95%CI=2.3-4.2). Patients with an organic disorder of the proximal part of the GI tract 
used more antidepressants or benzodiazepines (42% vs. 8%; OR=8.6; 95%CI=5.4-14.0) in 
comparison to patients without an organic abnormality. Patients with organic abnormalities in the 
proximal GI tract other than peptic ulcer, carcinoma or esophageal reflux disease all used some 
sort of psychotropic medication. There was no difference in the use of psychotropic medication 
between patients without organic abnormalities referred for upper and lower GI endoscopy. 
 
Figure 1: percentages of anxiety and depression in patients with gastrointestinal diseases.
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Patients with functional upper GI disease reported anxiety most often (35%) (Figure 1). Patients 
referred for upper GI endoscopy were more anxious than patients referred for lower GI 
endoscopy (OR=1.6; 95%CI=1.2-1.9). Thirty-nine percent of the patients with peptic ulcer 
disease reported anxiety and 33% was depressed. Overall, there was no difference in anxiety nor 
depression between patients with functional GI diseases and patients with an organic abnormality 
at upper GI endoscopy (OR=1.2; CI=0.8-1.7 and OR=0.9; CI=0.6-1.3 respectively) and at lower 
GI endoscopy (OR=1.0; CI=0.6-1.5 and OR=0.9; CI=0.6-1.4, respectively). However, patients 
diagnosed with colonic polyps were more anxious and depressed than other patients referred for 
lower GI endoscopy (OR=1.7; 95%CI=1.0-2.9 and OR=1.8; 95%CI=1.1-3.1, respectively) 
(Table 2). 
 
Table 2. Anxiety and depression and findings at endoscopy 
  Anxiety Depression 
 
No. of 
patients % OR (95% CI)* % OR (95% CI)* 
      
Upper GI endoscopy 600 34 1.6 (1.2-1.9) 28 1.2 (0.9-1.5) 
Carcinoma 7 14 0.4 (0.0-2.8) 50 2.2 (0.4-12.3) 
Peptic ulcer 33 39 1.5 (0.7-3.2) 33 1.5 (0.7-3.1) 
Reflux oesophagitis 132 33 1.0 (0.7-1.6) 28 1.1 (0.7-1.7) 
Hiatic hernia  41 34 1.0 (0.5-2.0) 29 1.1 (0.5-2.1) 
Other** 67 36 0.3 (0.1-0.6) 28 0.2 (0.1-0.5) 
functional† 320 35 1.2 (0.8-1.7) 28 1.1 (0.8-1.6) 
     
Lower GI endoscopy 698 25 0.7 (0.5-0.9) 24 0.8 (0.7-1.1) 
Carcinoma 8 25 1.0 (0.2-4.6) 0 n.a. 
Colitis 23 17 0.5 (0.1-1.4) 17 0.7 (0.2-2.0) 
Polyps 78 32 1.7 (1.0-2.9) 33 1.8 (1.1-3.1) 
Diverticles 16 13 0.4 (0.1-1.5) 31 1.1 (0.3-3.3) 
Other** 8 13 0.1 (0.0-1.0) 0 n.a. 
functional† 565 25 1.0 (0.6-1.5) 23 0.9 (0.6-1.4) 
*  OR’s are among disorders of the same part of the GI tract (i.e. proximal or distal) and adjusted 
for gender, age and use of psychotropic medication. 
**  Other organic abnormalities found at endoscopy, e.g. esophageal varices, fungus, stomach 
resection. 
†  No abnormalities found at endoscopy. 
 
DISCUSSION 
 
The results from several studies showed that patients with functional gastrointestinal (GI) disease 
are more anxious and depressed than healthy controls (4-10,13,16). However, data comparing 
patients with functional GI diseases with patients with an organic cause for their symptoms are 
limited. This study was therefore performed to determine the prevalence of anxiety and 
depression and its association with endoscopic findings in a representative sample of patients 
with gastrointestinal symptoms. Our results showed that patients referred for upper GI 
endoscopy are significantly more anxious than those referred for lower GI endoscopy. Although 
less anxious and depressed than patients referred for upper GI endoscopy, anxiety or depression 
is still reported by a quarter of all patients referred for lower GI endoscopy.  
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Psychotropic medication use among patients referred for GI endoscopy is high. There was no 
data available about reasons of prescription. Patients referred for upper GI endoscopy, especially 
those with an organic cause of their symptoms, consume more psychotropic medication than 
patients referred for lower GI endoscopy. This may have at least two explanations: since a lot of 
patients with GI symptoms are also anxious and depressed, it is very well possible that they use 
psychotropic medication to suppress their psychological complaints. Secondly, in The 
Netherlands, psychotropic agents are among the five most prescribed medicine (21). It is well 
known that antidepressants have GI side-effects. Thus it is possible that these patients have GI 
abnormalities as a side-effect of their psychotropic medication.  
 
O’Malley and colleagues (1998) found that the presence of any psychiatric disorder makes it 
unlikely that upper GI endoscopy will reveal significant GI abnormalities. Although their results 
lack evidence for an association with anxiety disorders, they conclude that mood and somatoform 
disorders are associated with endoscopy outcomes. This discrepancy with our study results might 
be explained by some differences in study design: firstly, we have included patients that might 
have been referred for a follow-up endoscopy, while the study by O’Malley included only patients 
with unexplained GI symptoms. In addition, they used a different diagnostic psychiatric test that 
assessed psychiatric disorders in general, including somatoform disorders, alcohol abuse and 
eating disorders whereas we used a validated specific anxiety and depression scale (17-19). 
Besides this, the study population of O’Malley et al. consisted of only 116 subjects, of whom only 
29 (25%) had major endoscopic abnormalities.  
 
There is no difference in anxiety and depression among patients referred for lower 
gastrointestinal endoscopy between those with functional and organic causes of their symptoms. 
However, a remarkable conclusion is that patients diagnosed with colonic polyps are more 
anxious and depressed than other patients referred for lower GI endoscopy. There are some 
explanations imaginable for this finding: firstly, due to the genetic pattern, it is very well possible 
that these patients have relatives with colonic polyps or cancer and are anxious or depressed 
because they recognize the symptoms, or their physician told them that they are at increased risk 
of developing polyps themselves. Secondly, it is possible that some of them were already familiar 
with their diagnosis and were referred for a follow-up endoscopy. At last, since many groups 
were compared, it is possible that this finding is due to chance. Either way, clinicians dealing with 
patients with colonic polyps should be aware of possible underlying psychological abnormalities 
and take appropriate action when needed. 
 
The division of patients according to endoscopy outcomes may have caused some limitations to 
the interpretation of results. For example, many patients with functional upper GI disease have 
an asymptomatic hernia. In addition, it is well known that at random endoscopy, polyps and 
diverticula’s will be found in a significant part of the population (23-24). However, assuming that 
all subjects were referred for GI endoscopy for a legitimate reason (i.e. persistent GI symptoms), 
this division seems justifiable. The fact that many of these organic abnormalities are present in 
asymptomatic subjects, does not change anything to the possibility that they explain symptoms in 
patients presenting to the gastroenterologists’ practice.  
 
Although we included patients referred for their first endoscopy, one-third indicated to have had 
a previous endoscopy. It should be noted that high levels of anxiety or depression cannot be 
explained by fear for the procedure, since the HADS questionnaire measures generalized anxiety 
and depression only. Furthermore, we assumed that the effect of a previous endoscopy on 
anxiety or depression would be canceled out after six months. Therefore, patients who had an 
endoscopy in the past six months before enrollment were excluded from further analysis. 
Besides, patients who underwent a previous endoscopy were not more anxious or depressed in  
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comparison to patients with and without an organic abnormality who were referred for their first 
endoscopy. 
 
The response rate to the first questionnaire is quite low. Possibly, this is due to the fact that all 
patients referred for GI endoscopy received a questionnaire. A certain part may have judged 
themselves not eligible for participation in this trial because they had a recent endoscopy, or 
insufficient control of the Dutch language. The low response rate may have given a distorted 
view of anxiety and depression rates in the studied population. It is very well possible that 
patients with an psychiatric disorder are more likely or unlikely than others to return the 
questionnaire.  
 
In conclusion, patients referred for upper gastrointestinal endoscopy are more anxious and use 
more psychotropic medication compared to patients referred for lower gastrointestinal 
endoscopy. Patients with colonic polyps are more anxious and depressed than other patients 
referred for lower GI endoscopy. There is no difference in anxiety nor depression between 
patients with an organic cause for their symptoms and patients with functional GI disease. 
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Background & Aim: Serotonin is associated with symptoms of the irritable bowel syndrome, its 
action is terminated by the serotonin transporter protein. The aim of this meta-analysis is to 
assess the association between a functional polymorphism in the gene encoding for activity of the 
serotonin transporter protein and the irritable bowel syndrome. 
Methods: Meta-analysis of studies identified through a Medline, PubMed and Web of Science 
search, describing the prevalence of a polymorphism in the serotonin transporter gene creating 
long and short alleles.  
Results: Eight eligible studies described a total of 1034 patients with the irritable bowel syndrome, 
and 1377 healthy controls. Presence of the short allele is not associated with an increased risk for 
the irritable bowel syndrome: OR 1.0; 95%CI=0.7-1.4 for homozygous subjects, and OR 1.0; 
95%CI=0.8-1.2 for homozygous subjects and heterozygotes together. Although Caucasians and 
Asians had diverging genotypic frequencies, no association with the short allele and irritable 
bowel syndrome was observed in subgroups: Asians OR 1.2; 95%CI=0.9-1.6 and OR 1.1; 
95%CI=0.2-5.9; Caucasians OR 0.9; 95%CI=0.5-1.7 and OR 0.9; 95%CI=0.7-1.2, both 
respectively for homozygous subjects alone and for homozygous subjects and heterozygotes 
together. 
Conclusion: A genetic polymorphism in the gene encoding for activity of the serotonin transporter 
protein is not associated with the irritable bowel. 
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INTRODUCTION  
 
The irritable bowel syndrome (IBS) is a chronic illness that affects approximately 15% of the 
adult population, and about 70% of affected individuals is female (1,2). Symptoms include 
abdominal pain, discomfort and altered bowel habits. Several subtypes have been identified based 
on predominant bowel habit: diarrhoea-predominant IBS (D-IBS) if diarrhoea is the predominant 
symptom; constipation-predominant IBS (C-IBS) if constipation is the predominant symptom; 
and alternating IBS (A-IBS) if patients have alternating diarrhoea and constipation.  
 
Despite the large amount of studies conducted, the etiology of symptoms remains largely 
unknown. It has been postulated that at least a large part of patients has visceral hypersensitivity 
and disturbed motility of the gut wall (3,4). These mechanisms are largely controlled by the 
enteric nervous system, in which serotonin is a key neurotransmitter. An increased level of 
serotonin is known to cause increased motility and excretion, and has been associated with 
symptoms such as diarrhoea, nausea and vomiting (5,6). 
 
Serotonergic action is terminated through reuptake from the synaptic cleft by the serotonin 
tranporter protein (SERT-P). This protein is encoded by a single gene on chromosome 17q11 
and is composed of 14 exons (7). There is a 44 bp insertion/deletion in the ‘5 flanking promoter 
region (5-HTTLPR), which creates a short and a long allele. It has been shown that the presence 
of the short allele is associated with lower transcriptional activity and, as a consequence, lower 
levels of SERT-P expression and reuptake of serotonin (8). 
 
Several studies have investigated the association between this functional polymorphism and IBS, 
with contradicting results (9-15): in a study from Turkey with 54 patients with IBS it was found 
that the short/short genotype occurred with a greater frequency in patients with C-IBS than in 
patients with D-IBS or A-IBS (11), two other studies with 190 and 194 patients with IBS 
respectively concluded that the short/short genotype was more frequent in patients with D-IBS 
(10,15), while another study with 276 patients found no association at all (14).  
 
There is a strong need for a structured analysis of these diverging results. Therefore, a meta-
analysis of all published data was performed, in order to investigate the true association between 
this polymorphism and the IBS subtypes.  
 
METHODS 
 
IDENTIFICATION AND SELECTION OF PUBLICATIONS 
 
A literature search was performed in May 2007. Relevant publications were identified using the 
following search terms in Medline, PubMed and Web of Science: ‘IBS and SERT’, ‘irritable bowel 
syndrome and SERT’, ‘serotonin transporter and IBS’, ‘irritable bowel syndrome and serotonin 
transporter’. Additional publications were retrieved by reviewing the references of selected 
studies. In order to be selected, publications had to fulfill the following criteria: (i) it had to be 
clear what patients were included and whether they were of the constipation-, diarrhoea- or 
alternating IBS subtype, (ii) frequencies of the 3 genotypes had to be clearly stated or could be 
calculated and (iii) a healthy control population had to be included and genotyped. 
 
DATA ANALYSIS 
 
Meta-analysis calculation was performed using Review Manager 4.2.8 by the Cochrane 
Collaboration 2005. Combined odds ratios with 95% confidence limits were calculated for the 
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risk of respectively IBS, D-IBS, C-IBS, and A-IBS in patients homozygous for the short allele in 
comparison to patients either heterozygous or homozygous for the long allele. If pooled analysis 
were statistically significant heterogeneous (p<0.01) using X2 test, random effect models were 
used, otherwise a fixed model was used. Study weights were calculated by the Review Manager 
software and are based on the standard error. The confidence intervals and p-values for statistical 
significance are reported using a two-tailed method. 
 
To address the problem of publication bias a funnel plot was prepared by plotting the log of the 
effect size for each of the published studies on the horizontal axis and the precision of these 
effects on the vertical axis. Using a log transformation of the effect size ensures that negative and 
positive effects are equally spaced. Furthermore, Chi-square analysis was used to calculate Hardy-
Weinberg equilibrium in order to evaluate genotype distribution. To adjust for multiple testing, a 
p-value <0.01 was considered statistically significant. 
 
RESULTS 
 
Literature search identified a total of 72 papers, of which 64 had to be excluded due to various 
reasons (Table 1). The remaining 8 studies, all case-control studies, described a total of 1034 
patients with IBS, 322 patients with constipation predominant IBS, 576 patients with diarrhea 
predominant IBS, and 1377 healthy controls. This resulted in 891 subjects homozygous for the 
short allele, and 1520 subjects either homozygous for the long allele or heterozygotes. All 
genotyped populations, both patients as well as controls, were in Hardy-Weinberg equilibrium 
(p>0.01), except for the patients described by Yeo et al. (Χ2=20.7; p-value <0.01).  
 
Table 1: Eligibility of manuscripts. 
Selected  72 
Excluded Total  64 
 Reviews, overview or commentaries (16-41)  26
 Study in children (42,43)  2
 Subjects did not have IBS (44-46)  3
 No or incomplete data on SERT-P polymorphism (47-66)  20
 Animal studies(67-76)  10
 Unfamiliar foreign language(77)  1
 No healthy control population included(9,12)  2
Included  (10,11,13-15,78-80) 8 
 
When the genotypes of all populations were combined to one large study sample, there was no 
Hardy-Weinberg equilibrium (Χ2=32.7; p<0.01 and Χ2=28.2; p<0.01 for patients and controls 
respectively). Both patients as well as controls originated from various geographical regions and 
ethnical populations; five studies were conducted in Caucasians and 3 in Asians. Among 
Caucasians, the homozygous short genotype was least common (22% of patients), but still 
present in a considerable proportion. In Asians, the far majority of patients was homozygous for 
the short allele (64%), while only a small proportion was homozygous for the long allele (6%) 
(figure 1). Both patients as well as controls of these ethnical subpopulations were in Hardy-
Weinberg equilibrium (p-value >0.01).  
 
Diverging inclusion criteria were used to identify patients with IBS: 2 studies used the Rome I 
criteria to identify patients, five studies (incl. all studies conducted in Asia) used the Rome II 
criteria, and 1 study used a selection of previously investigated patients from an administrative 
database (Table 2).  
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In the complete population, presence of the short allele was not associated with an altered risk 
for IBS in comparison to subjects homozygous for the long allele (OR 1.0; 95%CI=0.8-1.2) 
(figure 2). Subjects homozygous for the short allele alone did not show an altered risk for IBS 
either: OR 1.0; 95%CI=0.7-1.4, in comparison to heterozygotes and subjects homozygous for the 
long allele (figure 3). Also analysis of Asians and Caucasians separately, because of the large 
difference in genotype frequencies, did not reveal an altered risk for IBS in subjects with at least 
one short allele and subjects homozygous for the short allele: Asians OR 1.1; 95%CI=0.2-5.9, 
and OR 1.2; 95%CI=0.9-1.6 respectively, and Caucasians OR 0.9; 95%CI=0.7-1.2, and OR 0.9; 
95%CI=0.5-1.7 respectively. There were also no associations observed between the 
polymorphism and any of the IBS subtypes (Table 3).  
 
 
 
 
Table 3: Odds ratios (95% CI) for IBS with either one or two short 
allele(s) in Asians and Caucasians  
 IBS D-IBS C-IBS 
short/short vs. short/long or long/long 
All 1.0 (0.7-1.4)* 0.9 (0.5-1.5)* 0.9 (0.6-1.2) 
Caucasian 0.9 (0.5-1.7)* 0.7 (0.3-1.7)* 0.7 (0.5-1.1) 
Asian 1.2 (0.9-1.6) 1.3 (0.9-1.9) 1.0 (0.7-1.6) 
short/short or short/long vs. long/long 
All 1.0 (0.8-1.2) 1.0 (0.8-1.3) 0.7 (0.5-1.0) 
Caucasian 0.9 (0.7-1.2) 0.9 (0.7-1.2) 0.8 (0.5-1.1) 
Asian 1.1 (0.2-5.9)* 2.6 (0.8-7.9) 0.5(0.3-1.0) 
* random effects model 
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Figure 2: Odds-ratios (OR) for IBS in subjects either homozygous for the short allele or 
heterozygotes, compared to subjects homozygous for the long allele. 
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Figure 3: Odds-ratios (OR) for IBS in subjects homozygous for the short allele, compared to 
either homozygous for the long allele or heterozygotes. 
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Figure 4: Funnel plot indicating publication bias. 
 
 
The x-axis indicates the effect size that the homozygous short allele has on finding 
IBS. The y-axis is a measure of the precision of the estimate of the this effect: the 
smaller the confidence intervals, the more precise the estimate, the higher the dot 
representing that study is placed. The vertical line indicates where the pooled estimate 
from the meta-analysis lies. Although only few studies were included, this funnel plot 
shows no clear signs of publication bias. 
 
DISCUSSION 
 
Serotonin is currently probably the most studied neurotransmitter involved in symptom 
generation in functional gastrointestinal disorders, and in IBS in particular. Since serotonergic 
action is terminated by reuptake from the synaptic cleft by the serotonin transporter (SERT), a 
functional polymorphism in the gene encoding for this protein has been extensively investigated. 
Contradicting results were obtained, which makes it hard to speculate about the true association 
between this polymorphism and IBS. Moreover, studies were conducted in various populations, 
used different criteria for the definition of IBS and included sample sizes were relatively small. By 
combining all these data in this structured analysis, considerable sample sizes were obtained and 
it was shown that there is no association between the genetic polymorphism encoding for SERT-
P activity and IBS. 
 
In vivo experiments have shown that the short allele of the SERT-P gene leads to a reduced 
SERT transcription, resulting in higher synaptic serotonin levels (8,81). However, the functional 
consequences and the effect on the human phenotype remain unclear. It has been speculated that 
persisting high serotonin levels might down regulate serotonin receptors, thereby decreasing the 
serotonergic effect and as a consequence bowel motility (11). Indeed chronic suppression of 
SERT-P, which induces persistent availability of serotonin (5-HT), leads to internalisation of 5-
HT3 receptors (82). Conversely, continuously higher levels of serotonin cause increased bowel 
motility and secretion and, subsequently, diarrhoea. Support for either hypothesis can be found in 
animal experiments, as mice that lack SERT-P have alternating episodes of slow colonic transit 
and diarrhea (83). The current results show that, although the genotypes have been shown to 
influence SERT-P activity and might influence treatment response, the effects of altered SERT-P 
functioning observed in in vivo and animal experiments do not translate to the human phenotype 
in that they are associated with IBS or any of the subtypes. 
0.1  0.2  0.5 1 2 5  10
0.0
0.1
0.2
0.3
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SE(log OR)
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In genetic association studies it is of utmost importance to assess whether a representative sample 
has been analyzed and that the distribution of the various genotypes within that specific 
population satisfies expectations based on evolutionary fundamentals. One of the included 
patient populations was not in Hardy-Weinberg equilibrium. This might be due to random 
chance, usage of an erroneous method for genotyping or inclusion of a small and/or selective 
population (84). The authors of the study claim that the deviation from Hardy-Weinberg 
equilibrium in their patients reflects the genotypic associations with the extremely heterogeneous 
disorder D-IBS. This is not unlikely, and considering that by combining all studies and creating 
ethnic subpopulations the Hardy-Weinberg equilibrium is restored, the deviation is apparently 
not so large that it might have had influence on the current results.  
 
As with every meta-analysis, publication bias has to be considered; negative genetic studies are 
less likely to get published and there might be an overrepresentation of results showing an 
association between the polymorphism and the investigated disorder. In the case of IBS, 
however, this is slightly different. Considering the opposing characteristics of the IBS subtypes, 
positive as well as negative associations are relevant and publication bias is therefore less likely 
than with other, more homogeneous disorders. This is confirmed by the funnel plot showing 
that, in this meta-analysis, few and mostly low powered but both positive as well as negative 
studies were included.  
 
In conclusion, serotonin is an important mediator in gut sensibility and motility. Activity of the 
protein responsible for its reuptake has been associated with IBS-like symptoms in in vivo and 
animal experiments. The current analysis of previously published, contradicting data shows that 
there is no association between the genetic polymorphism in the SERT-P gene and IBS. The 
influence serotonin has on symptom development in IBS is probably merely associated with 
synthesis and release upon stimulation, rather than hereditary functioning of its reuptake protein.  
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AND ENDOSCOPIC FINDINGS? 
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M. Witteman, Adriaan C.I.T.L. Tan, Jan B.M.J. Jansen.  
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Background & Aim: The total number of upper gastrointestinal endoscopies is increasing, and 
despite guidelines for endoscopy referral for general practitioners, the proportion of patients 
without endoscopic abnormalities is still up to 60% (and increasing). The aim of this study was to 
assess the association between general practitioners’ referral indications and endoscopic findings. 
Methods: General practitioners of patients referred for an open access endoscopy between January 
2002 and December 2004 were asked to specify the reason for referral on a specially designed 
form. For each referral indication, the relative frequency of patients actually having an 
endoscopic abnormality was assessed. 
Results: A total of 1298 subjects was included. A relevant endoscopic disorder was found in 48% 
of patients. Patients with an endoscopic disorder were not more often referred with alarm 
symptoms or empirical treatment failure than patients without an endoscopic disorder (31% with 
an endoscopic disorder vs 30% without endoscopic disorder had alarm symptoms; 57% in both 
groups experienced empirical treatment failure). Referral with alarm symptoms had a positive 
predictive value (PPV) of 4% for cancer (prevalence was 2%; p<0.01), and referral with reflux-
like symptoms had a PPV of 33% for finding reflux-oesophagitis (prevalence was 22%; p<0.01). 
Conclusion: General practitioners’ referral indications for open-access endoscopy did not add any 
relevant predictive value for endoscopic findings in comparison with what might have been 
expected from overall prevalence. Only alarm symptoms slightly increased the probability of 
finding cancer and only reflux-like symptoms slightly increased the probability of finding reflux 
esophagitis.  
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INTRODUCTION 
 
Up to 60% of patients with persistent dyspeptic symptoms who are referred for upper 
gastrointestinal (GI) endoscopy are found to have no organic abnormality at endoscopy (1,2). 
These patients are defined as having functional dyspepsia. Since upper GI endoscopy is an 
invasive and costly procedure, attempts have been made to increase the diagnostic yield by 
identifying patients that are most likely to benefit from the procedure.  
 
Guidelines have been developed for general practitioners to optimise the management of patients 
presenting with upper gastrointestinal (GI) symptoms. They suggest test-and-treat for Helicobacter 
pylori and empirical treatment with proton pump inhibitors (PPI) for patients with a first episode 
of upper abdominal symptoms (3,4). Upper GI endoscopy is indicated when alarm symptoms 
such as weight loss and dysphagia are present, age >55, and when empirical treatment with either 
PPIs or H. pylori eradication does not relieve symptoms. Furthermore, upper GI endoscopy is 
often performed when general practitioners and/or patients are uncertain about the origin of 
symptoms and seek reassurance that there is no serious pathology underlying (5). 
 
Although implementation of these guidelines is well established, diagnostic yield of an upper GI 
endoscopy remains low. The total number of upper GI endoscopies is increasing, while the 
frequency of organic abnormalities found at endoscopy is decreasing (6,7). Referral indications 
should be re-evaluated in order to gain insight in the reasons why general practitioners refer 
patients for this investigation and the relationship of these with endoscopic findings. The aim of 
this study was to assess the association between general practitioners’ referral indications and 
endoscopic findings. 
 
METHODS 
 
SUBJECTS 
 
Data were collected prospectively from consecutive patients referred to the Canisius-Wilhelmina 
Hospital in Nijmegen, the Netherlands, for open access upper gastrointestinal (GI) endoscopy 
between January 2001 and December 2004 by their general practitioner. The Canisius-Wilhelmina 
Hospital is a general secondary care district hospital. Patients were excluded from further analysis 
if they were under the age of 18, if they had been referred without a clear indication, if they had 
undergone an endoscopy in the preceding 6 months, or if they had a failed endoscopy. All 
aspects of the protocol were approved by the Medical Ethical Committees of University Medical 
Center St Radboud and the Canisius-Wilhelmina Hospital, both in Nijmegen, The Netherlands. 
 
DATA COLLECTION 
 
Patients underwent a routine diagnostic upper GI endoscopy and findings were entered into a 
database. The following organic abnormalities were identified: gastro-oesophageal carcinoma, 
Barrett’s oesophagus, reflux-oesophagitis, peptic and duodenal ulcer (PUD), and duodenitis (at 
least visible erosions).  
 
General practitioners filled in the referral indications on a standardized form. These referral 
indications were divided into four groups: alarm symptoms, empirical treatment failure, reflux-
like or dyspepsia-like symptoms. Patients referred with either weight loss, dysphagia or 
meleana/haematemesis were assigned to the alarm symptoms group. Patients who were referred 
because symptoms persisted during, or recurred after empirical treatment with protonpump 
inhibitors (PPI) or H. pylori eradication were considered to have empirical treatment failure. 
 53
Those who were referred with regurgitation, reflux or heartburn were classified as suffering from 
reflux-like symptoms and patients referred with upper abdominal complaints, dyspepsia, nausea, 
vomiting, pain, belching, or fullness were classified as having dyspepsia-like symptoms. Referral 
indications that could not be classified to one of these four groups, such as anaemia, NSAID use 
and psychological stress, were referred to as ‘Other’. When multiple endoscopic findings or 
several referral indications were present, patients were included in more than one diagnostic or 
indication group, respectively. 
 
STATISTICAL ANALYSES 
 
Statistical analysis was performed with SAS statistical software, version 8.2. Data were analysed 
by means of frequency tables and descriptive statistics. Frequencies of the respective referral 
indications in patients with and without an organic abnormality at endoscopy were compared 
using logistic regression analysis. Results where adjusted for age and gender.  
 
Positive predictive values (PPV) of the various referral indications were calculated. The PPV is 
the probability in terms of relative frequencies that patients presenting with a specific symptom 
actually have an organic abnormality. This depends on the prevalence of the disease in the 
population. The PPV assesses the additional diagnostic value of individual symptoms, compared 
with the prevalence of organic abnormalities in the total population. Chi-squared tests were used 
to compare PPVs with prevalences. Furthermore, negative predictive values were calculated in 
order to assess the probability that the a patient will not have the disease in the absence of a 
specific referral indication. To adjust for multiple testing, a two-sided p-value <0.01 was 
considered to be statistically significant. 
 
RESULTS 
 
A total of 1298 patients were included: 49% were male and mean (SD) age was 54(15) years. 
Patients with an organic abnormality were more often male (58%) than patients without an 
organic abnormality (44%) (p<0.01). There was no difference in mean age between patients with 
and without an organic disorder (54±15 and 53±15 respectively; p=0.16). Overall, a relevant 
organic abnormality was found in 48% of patients (Table 1). 
 
Table 1: Demographiccharacteristics and endoscopic findings of 
patients referred for open-access endoscopy.  
Number of patients 1298 
Mean age (years ±SD) 54 ±15 
Male gender 631 (49%) 
Endoscopic findings, N(%)  
Gastroesophageal carcinoma  23 (2) 
Barrett’s oesophagus 60 (5) 
Reflux oesophagitis  284 (24) 
PUD and duodenitis  127 (10) 
Functional dyspepsia 677 (52) 
Other 173 (13) 
 
When the frequencies of the four major referral indications were compared between patients with 
and without an endoscopic abnormality, only the proportions of patients referred with reflux-like 
symptoms  were statistically significantly different (55% and 41% respectively; p<0.01) (Figure 1). 
Empirical treatment failure was not, in general, more common in patients with an organic 
abnormality compared with patients without an abnormality. However, when analysing the 
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specific sub-indications, it appeared that patients with an organic disorder are more often referred 
for symptom relapse after initial treatment (29% vs 23%; p=0.02) and patients without an organic 
disorder more often are referred with symptoms that persisted despite treatment (35% vs 31%; 
p=0.3), these differences did not reach statistical significance though.  
 
Figure 1: frequencies of various referral indications for patients with and without an organic 
disorder found at upper GI endoscopy (adjusted for age and gender). 
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PPVs of the four major referral indications did not deviate substantially from prevalence of the 
specific organic disorders. If a patient was referred with alarm symptoms, the PPV for finding 
cancer increased to 4% (prevalence 2%; p<0.01), while the PPV for finding Barrett’s oesophagus  
was the same as the prevalence of this condition (5%). Empirical treatment failure had a PPV of 
only 1% for carcinoma and 5% for Barrett’s oesophagus. The PPV for reflux oesophagitis in 
patients referred with reflux-like symptoms was 33%; an increase of 9% compared to the 
prevalence (p<0.01) (Table 2). If there were no alarm symptoms or empirical treatment failure, it 
was almost certain that no cancer would be found: negative predictive values 99% and 97%, 
respectively 
 
 
*
*
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DISCUSSION 
 
In this large sample study we investigated general practitioners’ referral indications for open-
access endoscopy. Our data show that the probabilities of finding cancer and reflux oesophagitis 
in patients referred with alarm symptoms and reflux-like symptoms respectively are slightly 
increased, and that the probability of finding cancer is negligible in the absence of alarm 
symptoms. Overall, referral indications are not very useful as predictors of finding endoscopic 
abnormalities compared with what can be expected from the prevalence of the disorder in a 
general endoscopy population.  
 
Previous attempts have been made to identify clinical variables, such as alarm symptoms, 
symptom clusters and patient characteristics (e.g. age, clinical history) to increase endoscopic 
yield (8-12). Current guidelines prescribe empirical treatment with proton pump inhibitors or H. 
pylori eradication. Endoscopy is indicated if these two strategies have failed to relief symptoms, or 
when symptoms recur. Our data show that referral for empirical treatment failure does not 
increase the probability of finding an organic abnormality. These results are supported by Smith 
et al, who showed that the endoscopic yield in patients who fail to respond to empirical treatment 
is significantly lower than in patients who have an excellent response to PPI therapy (13). 
Furthermore, the finding that referral for alarm symptoms, although statistically significant, does 
not substantially contribute to finding an organic abnormality, is concordant with the findings of 
Wallace et al., who concluded that age and presence of “high risk” symptoms were both poor 
predictors of major endoscopic lesions in their study with of a very large number of patients with 
dyspepsia (10). The same conclusion was drawn from the results of a recent meta-analysis; results 
showed that the risk for upper GI malignancy is very low in patients presenting with alarm 
symptoms and that 25% of patients with an upper GI malignancy have no alarm symptoms at 
time of diagnosis (14).  
 
Patients presenting with dyspeptic symptoms represent a substantial part of the population 
consulting a general practitioner and a considerable number will be referred for endoscopy. From 
our results it is shown that only a minority of these patients will have an organic abnormality at 
open access endoscopy, of which over 90% has peptic ulcer disease (PUD) or reflux-
oesophagitis, this is consistent with results of other studies (10,15,16). When performing random 
endoscopy in the general population, a large proportion (19% to 90%) will have an abnormal 
endoscopy too, without any clinical symptoms (17-19). From this it can be concluded that in 
many patients, a so-called endoscopic abnormality does not explain persisting symptoms. 
Moreover, almost half of patients have been given antisecretory medication in the year preceding 
endoscopy and will continue using them after endoscopy (20). Current evidence suggests that 
most patients undergoing endoscopy for reflux-like symptoms are switched to PPI, regardless of 
the endoscopic findings (21). This suggests that the management of symptoms is hardly 
influenced by endoscopy itself. Only finding Barrett’s oesophagus and gastroesophageal 
carcinoma alters treatment strategy: given the stage at diagnosis, carcinoma leads to palliative 
treatment in the majority of cases and patients with Barrett’s oesophagus will usually be included 
in a surveillance endoscopy program. This latter strategy is currently under debate, meaning that 
the finding of Barrett’s oesophagus might not alter clinical management either but might instead 
be a reason to continue lifelong antisecretory therapy. 
 
Upper GI endoscopy is often performed to reassure patients or their physicians that there is no 
severe pathology underlying symptoms. Wiklund et al (22) showed that quality of life (QOL) was 
only improved for a short period after negative endoscopy. Bytzer et al (23) concluded that 
prompt endoscopy for the management of dyspepsia leads to no difference in terms of  QOL 
after 1 year. In a previous study, in which we compared anxiety, depression and QOL scores 
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before and one month after upper GI endoscopy in both patients with an organic disorder and  
in patents without any organic disorders, we found no relevant improvements in any of these 
factors(24).  
 
This large endoscopy based study provides an impression of how decisions are made in real 
clinical practice. Patients consult their general practitioner with a wide variety of upper GI 
complaints, and general practitioners determine management on the basis of guidelines. We 
divided patients into four major indication groups; alarm symptoms, empirical treatment failure, 
reflux-like symptoms and dyspepsia-like symptoms. This division is arbitrary and the accuracy of 
classification of patients into indication groups depended on the accuracy of the data provided by 
the general practitioners. Also, the grouping of patients according to endoscopic findings could 
have led to some misclassifications: although patients are requested to stop any acid-inhibiting 
medication 2 weeks prior to endoscopy, some organic disorders may have been masked. 
Consequently, a small proportion of patients now diagnosed with functional dyspepsia could 
have had reflux oesophagitis or peptic ulcer disease. However, since we used very large study 
samples, and subjects could be in more than one indication and endoscopic finding category, we 
assume that our results are representative of the population of people referred for an open-access 
upper GI endoscopy. 
 
In conclusion, it could be argued that, at least in the absence of alarm symptoms and treatment 
failure, endoscopy should not be performed. Although endoscopy accurately diagnoses many 
disorders of the proximal gastrointestinal tract, such as erosive oesophagitis, Barrett’s 
oesophagus, and peptic ulcer disease, the discovery of these disorders does not substantially 
influence treatment strategy. Endoscopy is an invasive and costly procedure, and is also not very 
likely to reassure a patient when no organic abnormalities that might explain their symptoms are 
found. Our results show that specific referral indications do not contribute to better prediction of 
relevant endoscopic findings. Given the low prevalence and generally incurable stage at diagnosis 
of cancer, physicians should not only focus on excluding malignancies, but also should consider 
ethical and socioeconomic factors when referring for an upper GI endoscopy. 
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Background & Aim: Alexithymia, where a person has difficulty to distinguish between emotions 
and bodily sensations, is considered to be a character trait and a vulnerability factor for various 
psychosomatic disorders. Assessing alexithymia in patients with gastrointestinal symptoms prior 
to endoscopy might therefore be useful in selecting patients that are more prone to functional 
gastrointestinal disorders. The aim of this study was to assess whether alexithymia might be a 
useful factor in predicting gastrointestinal endoscopy outcomes. 
Methods: Patients referred for endoscopy between February 2002 and February 2004 were 
enrolled. They were asked to report alexithymia on the Toronto Alexithymia Scale (TAS-20) two 
weeks prior to endoscopy. Information about endoscopic diagnoses was obtained from medical 
files.  
Results: A total of 1141 subjects was included (49% male), of whom 245 (21%) reported 
alexithymia. There was no difference in mean ±SD alexithymia scores between patients with 
(51±12) and without (50±12) an endoscopic organic abnormality at gastrointestinal endoscopy. 
When divided into subgroups, according to the most prominent finding at either upper or lower 
GI endoscopy, there was no association with alexithymia. Patients with alexithymia reported a 
worse sensation of gastrointestinal symptoms during the last weeks before enrollment in the 
study (mean ±SD symptom severity score: 42±34 vs 34±30; respectively; p<0.01). 
Conclusions: Alexithymia is not associated with endoscopic findings, and has therefore no additive 
value in predicting endoscopy outcomes. Patients with alexithymia more often present with more 
severe and a higher number of gastrointestinal symptoms. 
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INTRODUCTION  
 
In the majority of patients with gastrointestinal (GI) symptoms (40-80%), no pathological cause 
can be found (1,2). Efforts have been made to develop diagnostic tools and criteria for these so-
called functional GI diseases that might prevent invasive and expensive diagnostic interventions. 
It has been shown by Herschbach et al. that the tendency of patients with functional GI 
disorders to consult a physician is influenced by personality factors (3). In addition, many studies 
have shown that patients with functional dyspepsia are more anxious and depressed than healthy 
controls and patients with organic GI diseases (4-11). However, in a recent study we found that 
there is no difference in anxiety nor depression between patients with functional GI diseases and 
patients with organic abnormalities at endoscopy prior to diagnosis (12) This implies that 
psychological distress is merely a result of GI symptoms, rather than an etiological factor.  
 
A condition that has been associated with illness behavior and increased medical consumption is 
alexithymia. Although very common, alexithymia is a relatively unknown condition in the general 
clinical practice. Alexithymic patients are unable to describe emotions in words, are unaware of 
what their feelings are and have difficulty to distinguish between emotions and bodily sensations 
(13). They typically show an emotional coldness and a way of speaking that is only cognitive. This 
not only influences patient behavior, but also that of the caregiver: In a study by Rasting et al. it 
was shown that alexithymia greatly influences affective expression and that the predominant 
emotional reaction of a therapist to an alexithymic patient is contempt (14). 
 
Although not absolutely stable, alexithymia is considered a character trait and it has been found 
to be a vulnerability factor in different psychosomatic disorders such as essential hypertension, 
irritable bowel syndrome, obsessive compulsive disorder, panic disorder and depression (15-17). 
Alexithymic patients tend to have a lower life satisfaction in comparison to non-alexithymic 
controls (18). Recent studies have shown that patients with functional GI disorders are more 
alexithymic than patients with inflammatory bowel disease and healthy controls (19,20).  
 
The assumption that patients with functional GI diseases report higher rates of alexithymia than 
patients with an organic cause of their symptoms leads to the consideration that assessment of 
alexithymia prior to endoscopy might contribute to a reduction in expensive and invasive 
diagnostic interventions. It was hypothesized that the prevalence of alexithymia is higher in 
patients without an organic cause of their GI symptoms. Therefore, the objective of this study 
was to compare alexithymia prevalence rates between patients with and without an endoscopic 
organic cause of their GI symptoms prior to diagnosis.  
 
MATERIALS AND METHODS 
 
SUBJECTS 
 
Between February 2002 and February 2004, consecutive patients referred for upper or lower 
endoscopy to the Canisius-Wilhelmina Hospital in Nijmegen, The Netherlands, were asked to fill 
out a postal questionnaire 2 weeks prior to endoscopy. This is a general primary care district 
hospital. The questionnaire included enquiries on demographic information, alcohol and 
medication use, the presence and severity of upper and lower gastrointestinal symptoms and 
alexithymia. Information about the endoscopic and histological findings were collected after 
completion of the questionnaire. Questionnaires were processed with Teleform automatic 
scanning software version 6.0 (Cardiff Software inc.; Sunnyvale, CA, USA). All aspects of the 
protocol were approved by the Medical Ethical Committees of University Medical Center St 
Radboud and the Canisius-Wilhelmina Hospital, both in Nijmegen, The Netherlands.  
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ALEXITHYMIA 
 
Alexithymia was measured using the 20-item Toronto Alexithymia Scale (TAS-20). This is the 
most used questionnaire to assess alexithymia and has been carefully validated (21-24). It is a self-
completed questionnaire that can be used in a variety of clinical settings. It consists of 3 domains: 
difficulties in identifying feelings and distinguishing between emotional and physical sensations, 
difficulties in describing feelings and externally oriented thinking. The scale describes a total of 20 
items rated on a 5-point Likert scale (1=strongly disagree, 5=strongly agree). This way utilities 
can be calculated that indicate a patient’s rate of alexithymia. Alexithymia is defined as a score of 
more than 60 on the TAS-20 (25). 
 
ENDOSCOPY 
 
Patients underwent a routine diagnostic upper or lower gastrointestinal endoscopy. The results 
were entered into a database. Furthermore, histological data were obtained from the biopsies 
taken during endoscopy. These biopsies were analyzed by an experienced pathologist and results 
were entered into the same database. For this study, data concerning the outcomes of upper and 
lower gastrointestinal endoscopies were extracted from that database and patients were divided 
into groups according to their most prominent endoscopic outcome. Patients were defined as 
having an endoscopic organic disorder if their diagnosis was carcinoma, gastric or duodenal ulcer, 
reflux oesophagitis, hiatic hernia. colitis, polyps or diverticula. When no explanation for 
symptoms could be found at endoscopy, they were defined as functional. Patients who 
underwent an endoscopy in the past six months before enrollment were excluded from further 
analysis. 
 
SYMPTOM SCORE 
 
Patients were asked to fill out a questionnaire on gastrointestinal symptoms. This questionnaire 
included items on GI symptoms. Severity in the last four weeks was rated on a 7-point Likert 
scale (0 = absent and 6 = very severe). Items that were not scored properly by more than 10 
percent of the subjects were not taken into further analysis. A score of 2 or more was regarded as 
symptom presence. Furthermore, symptom severity in the last 4 weeks was scored on a 100mm 
Visual Analogue Scale (VAS).  
 
STATISTICAL ANALYSES 
 
Data at baseline were analyzed by means of frequency tables and descriptive statistics. Age and 
alcohol use adjusted regression analyses were performed to determine the odds ratios for 
endoscopy outcomes. Patients with incomplete data were excluded from analysis. Two-tailed t-
tests were performed to compare mean number of symptoms and mean severity scores between 
patients with and without alexithymia. Statistical significance was accepted at a p-value <0.05. 
Analysis was performed with SAS statistical software, version 8.0. 
 
RESULTS 
 
A total of 1141 subjects was included, of whom 580 (49%) were male. Mean age(±SD) was 
55(±15) years. Five hundred patients were referred for upper GI endoscopy, while 641 were 
referred for lower GI endoscopy. Of all 695 patients that underwent previous diagnostic 
interventions 495 had a previous endoscopy (Table 1). There were no differences in alexithymia 
scores between patients with and without a previous endocscopy. 
 
62 
Table 1: Patient characteristics  
 No. of patients (%) 
Mean age (years)(SD) 55 (15) 
Gender  
Male 
Female 
 
580  (49) 
561  (51) 
Previous endoscopy 495  (43) 
Other previous diagnostic intervention* 200  (18) 
Upper GI endoscopy  
Organic upper GI disease 
Functional upper GI disease 
500  (44) 
244  (49) 
256  (51) 
Lower GI endoscopy  
Organic lower GI disease 
Functional lower GI disease 
641  (56) 
148  (23) 
493  (77) 
* X-ray or Helicobacter Pylori test.  
 
Alexithymia was reported by 245 (21%) subjects and mean overall score(±SD) on the TAS was 
51(±12). Subjects who had a score of more than 60 were considered alexithymic but had an equal 
risk of having an organic abnormality at either upper or lower GI endoscopy (Odds Ratio (OR) 
1.0; 95%CI=0.7-1.6 both). When divided into subgroups none of the findings at endoscopy was 
associated with an increased risk for alexithymia (Table 2). Of the socio-demographic factors, 
alcohol use was associated with a decreased risk for alexithymia (OR 0.49; 95%CI=0.37-0.66) and 
age >50 years was identified as a risk factor (OR 1.52; 95%CI=1.11-2.11).  
 
Table 2: Odds ratios for alexithymia in different endoscopic findings. 
 N (%) alexithymic Unadjusted  OR (95% CI) 
Adjusted  
OR (95% CI)* 
Proximal (n=500) 104 (21)   
Carcinoma 2 (50) 3.86 (0.46-32.49) 3.39 (0.39-29.74) 
Ulcer 10 (29) 1.58 (0.70-3.31) 1.58 (0.69-3.40) 
Reflux 22 (19) 0.87 (0.51-1.46) 0.89 (0.51-1.49) 
Functional 52 (20) 0.94 (0.61-1.45) 0.91 (0.58-1.43) 
Other** 18 (20) 0.94 (0.52-1.63) 0.98 (0.54-1.73) 
    
Distal (n=641) 141 (22)   
Carcinoma 5 (31) 1.64 (0.51-4.58) 1.67 (0.51-4.77) 
Colitis 4 (17) 0.74 (0.21-2.01) 0.93 (0.26-2.59) 
Polyps 18 (23) 1.03 (0.58-1.78) 1.03 (0.56-1.81) 
Diverticulas 3 (23) 1.07 (0.24-3.54) 1.25 (0.27-4.39) 
Functional 107 (22) 0.93 (0.60-1.46) 0.87 (0.56-1.39) 
Other** 4 (25) 1.19 (0.33-3.47) 1.18 (0.32-3.52) 
    
Smoking 85 (25) 1.0 (0.87-1.13) 0.99 (0.86-1.13) 
Alcohol 118 (17) 0.5 (0.37-0.67) 0.49 (0.37-0.66) 
Age >50 yrs 68 (17) 1.58 (1.17-2.17) 1.52 (1.11-2.11) 
Male 117 (20) 0.86 (0.64-1.13) 1.03 (0.76-1.40) 
Previous endoscopy 117 (24) 1.25 (0.94-1.66) 1.12 (0.83-1.50) 
* OR’s are among disorders of the same part of the GI tract (i.e. proximal or distal) and adjusted for 
alcohol use, age >50 yrs and a previous endoscopy. 
** Other organic abnormalities found at endoscopy, e.g. esophageal varices, fungus, stomach resection. 
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As a result of improperly filled out questionnaires, all enquiries on stools had to be excluded. 
Sixteen items of the questionnaire were available for further analyses. Alexithymic subjects 
reported more GI symptoms (mean(±SD) 6(±4) vs 5(±3) p<0.05) and higher mean symptom 
severity scores (42(±34) vs 34(±30); p<0.01) in comparison to subjects who were not 
alexithymic. Patients referred for upper GI endoscopy reported more symptoms (6(±4) vs 4(±3); 
p<0.05) and higher symptom severity scores (42(±32) vs 32(±29); p<0.01) compared with 
patients referred for lower GI endoscopy. Among patients referred for lower GI endoscopy, 
patients with no endoscopic organic abnormalities reported higher symptom severity scores than 
patients with an organic explanation for their symptoms (33(±29) vs 26(±27); p=0.02). We found 
no difference in mean number of symptoms between patients with and without an endoscopic 
organic explanation for their symptoms at both upper and lower GI endoscopy (Figure 1). 
 
Figure 1: Mean VAS scores and mean number of symptoms in patients with and without 
organic abnormalities at gastrointestinal endosopy
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When analyzing each symptom separately, almost all of the reported symptoms seem to be 
associated with an increased risk for alexithymia, even more after adjustment for age and alcohol 
use. Especially patients with haematemesis (OR 3.7; 95%CI=1.5-9.2), abdominal pain (OR 1.8; 
95%CI=1.4-2.5) and vomiting (OR 1.9; 95%CI=1.2-3.0) are frequently alexithymic (Table 3). 
The presence of more than 8 symptoms, of total 16, is associated with a more than twofold risk 
for alexithymia (OR 2.1; 95%CI=1.5-2.9, adjusted for age (OR 2.6, 95%CI=1.8-3.7) (Figure 2).  
p=0.02 
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Table 3: Alexithymia and gastrointestinal symptoms 
 Presence 
N 
Alexithymia 
% 
Unadjusted 
OR (95% CI) 
Adjusted* 
OR (95% CI) 
Abdominal pain  456 27 1.7 (1.3-2.2) 1.8 (1.4-2.5) 
Epigastric pain 405 25 1.4 (1.0-1.8) 1.5 (1.1-2.0) 
Heartburn 348 25 1.3 (1.0-1.8) 1.4 (1.0-1.9) 
Regurgitation 392 26 1.4 (1.1-1.9) 1.5 (1.1-2.0) 
Abdominal rumbling 619 21 1.0 (0.8-1.3) 1.1 (0.8-1.5) 
Bloating 588 26 1.3 (1.0-1.7) 1.3 (1.0-1.8) 
Empty feeling  244 26 1.4 (1.0-1.9) 1.7 (1.2-2.4) 
Nausea 303 25 1.3 (1.0-1.8) 1.4 (1.0-1.9) 
Vomiting 110 33 1.9 (1.2-2.9) 1.9 (1.2-3.0) 
Loss of appetite 252 29 1.7 (1.2-2.3) 1.6 (1.2-2.3) 
Postprandial fullness 427 26 1.5 (1.1-2.0) 1.6 (1.2-2.1) 
Belching 486 23 1.2 (0.9-1.6) 1.2 (0.9-1.6) 
Flatulence 743 22 1.2 (0.9-1.6) 1.3 (0.9-1.7) 
Heamatemesis 22 45 3.1 (1.3-7.4) 3.7 (1.5-9.2)) 
Dysphagia liquid food 70 31 1.7 (1.0-2.9) 1.7 (1.0-3.0) 
Dysphagia solid food 126 29 1.5 (1.0-2.3) 1.5 (1.0-2.3) 
*OR’s are adjusted for alcohol use and age >50 yrs 
 
 
Figure 2: Association between number of symptoms and alexithymia.
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DISCUSSION 
 
We hypothesized that the assessment of alexithymia could be helpful in selecting patients with 
gastrointestinal symptoms to prevent invasive and expensive further diagnostic procedures. In 
this study we found no difference in prevalence of alexithymia between patients with and without 
an endoscopic organic cause for their symptoms. Patients with alexithymia present with more 
severe and a higher number of symptoms.  
 
In other studies where alexithymia was assessed in patients with functional gastrointestinal 
diseases, mean scores on the TAS-20 were compared with scores of other patients or healthy 
controls. Mean scores in healthy subjects (i.e. students and comparable controls) range from 41 
to 45, which is lower than the mean scores we found in our patient population. On the other 
hand, mean scores in patients with functional GI disorders (i.e. functional dyspepsia and irritable 
bowel syndrome) range from 52 to 59 and are in accordance with our results (19,26-28). This 
indicates that alexithymia is more common among patients presenting with GI symptoms than in 
a healthy population. Jones et al. recently found the same results in their study comparing 
alexithymia and somatosensory amplification between patients with functional dyspepsia and 
healthy controls. They concluded that alexithymia might play a role in symptom generation and 
perception, but the connection they found was less strong than previously reported (29). 
 
The finding that patients with alexithymia present with a higher number and more severe 
symptoms is in accordance with the results of Chou et al. (30). This group reported that 
functional dyspeptic patients with high depression scores report a higher total number of 
symptoms, compared with non-depressed patients with functional dyspepsia. There was no 
difference between total symptom severity scores, however, depressed patients reported 
significantly higher severity scores on specific symptoms. 
 
Although recent findings suggest that alexithymia is a multidimensional construct, in general, a 
score of more than 60 on the TAS is considered indicative for alexithymia. Many studies used 
mean TAS-scores, instead of this cutoff point to assess differences in alexithymia. Using both 
this cutoff point and mean scores, we found no difference between patients with and without an 
organic cause for their symptoms. The absence of a difference might imply that the studied 
population, that is patients presenting to the general practitioner or gastroenterology practice 
with abdominal symptoms, is a selected group. It is possible that alexithymic patients consult a 
physician more easy and more often in comparison to non-alexithymics, no matter the cause of 
their symptoms. This is in accordance with the fact that subjects with functional GI disorders on 
average have higher alexithymia scores than healthy subjects. Another explanation could be that 
the absence of an organic abnormality at endoscopy does not mean that there is no organic 
disorder that might have explained symptoms: many patients with gastric reflux disease and 
peptic ulcer disease have no abnormalities at endoscopy and some patients might have had 
disorders that were undetectable by endoscopy, such as gallstones, mesenteric ischemia, mild 
pancreatitis or sugar malabsorption. Hence the group with functional GI diseases might include 
some of these patients. Fact remains that, among these patients, alexithymia has no predictive 
value for the outcome of endoscopy.  
 
In conclusion, alexithymia has no value in predicting endoscopy outcomes, and, with that, 
prevention of expensive and invasive procedures in patients with GI symptoms. However, when 
dealing with a patient with many and more severe symptoms, alexithymia should be considered 
and attention should be paid to related disorders such as depression and essential hypertension. 
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Background & Aim: The Rome criteria have been introduced to create order in the heterogeneity 
of functional dyspepsia. The applicability of these symptom-based classification systems remains 
controversial. The aim of this study is to evaluate the successive Rome criteria for functional 
dyspepsia in a large pool of patients with endoscopically verified functional dyspepsia. 
Methods: Patients referred to a secondary care district hospital were asked to fill out a 
questionnaire on gastrointestinal symptoms 2 weeks before upper gastrointestinal endoscopy. 
Patients were classified according to the Rome I, II and III criteria for functional dyspepsia.  
Results: 912 (70%) patients had no organic disorder explaining their symptoms. According to the 
Rome I, II, and III criteria, respectively 371 (41%), 735 (81%), and 551 (60%) of these patients 
had functional dyspepsia. Twenty-five percent of patients had functional dyspepsia according to 
all 3 Rome criteria, while 15% was not classifiable at all. Forty-four percent and 42% of the 
patients respectively had epigastric pain syndrome (EPS) and postprandial distress syndrome 
(PDS) according to the Rome III criteria, however, 26% of all patients met both criteria and 40% 
was not classified at all.  
Conclusion: The symptom-based Rome classification of functional dyspepsia does not lead to an 
easily applicable and consistent system that is useful in clinical practice or scientific research. 
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INTRODUCTION 
 
Upper gastrointestinal symptoms are common with an annual prevalence in western countries of 
approximately 25-40%. In up to 60% of these patients no organic disorder is found if upper 
gastrointestinal endoscopy is performed that might explain their symptoms, and they are 
diagnosed with functional dyspepsia (1,2). The etiology of this condition remains unclear, but 
other disorders such as the irritable bowel syndrome and particularly gastroesopheal reflux 
disease (GERD) often coexist (3,4).  
 
Various attempts have been made to define subclasses of patients with gastrointestinal symptoms 
without a clearly defined organic cause that might explain their symptoms and may direct 
treatment. The first attempt to diagnose patients by a cluster of symptoms were the Manning 
criteria, in 1978, followed by a study by Kruis et al, both describing a set of symptoms that were 
characteristic for irritable bowel syndrome (5,6). These two symptom-based definitions have 
formed the basis for current definitions of many functional gastrointestinal diseases, of which the 
Rome criteria are probably the most well-known (7). Recently the results from a new meeting, the 
Rome III criteria which define a total of 28 adult and 17 pediatric functional gastrointestinal 
diseases, were published (8). 
 
Functional dyspepsia, the most prevalent and well-known functional gastrointestinal disorder of 
the proximal gut, was already defined by the Rome I criteria (9). In the Rome II criteria this 
definition was refined, and subgroups were introduced on the basis of predominant symptom 
(10). In the current Rome III criteria functional dyspepsia is divided into 2 new disorders: 
postprandial distress syndrome and epigastric pain syndrome (11). These conditions seem similar 
to the dysmotility-like and ulcer-like dyspepsia subgroups described by the Rome II criteria (12), 
except that they are now based on a complex of symptoms, rather than on predominant 
symptoms.  
 
Defining subgroups of patients based on symptoms seems very natural, but has significant 
limitations in clinical practice. Symptom-based classification implicates that there are differences 
in etiology and therapeutic options, but thus far, symptom-based treatment has obtained 
contradicting results in a research setting (13,14). Furthermore, symptoms-based classification 
only makes sense when symptom patterns are unique and stable over time. For both functional 
dyspepsia as well as IBS, studies have documented that there is substantial overlap between 
subgroups, the predominant symptom may change over time and a large proportion (7-15%) of 
patients are not classifiable at all (15,16).  
 
The aim of this study was to evaluate the applicability and consistency of the classification of 
functional dyspepsia according to the consecutive Rome definitions in a large sample of patients 
with upper gastrointestinal symptoms who had a normal endoscopy.  
 
MATERIALS AND METHODS 
 
SUBJECTS 
 
Between February 2002 and February 2004, consecutive patients referred for an open access 
upper gastrointestinal endoscopy to the Canisius-Wilhelmina Hospital in Nijmegen, The 
Netherlands, were asked to fill out a valid postal questionnaire 2 weeks prior to endoscopy. This 
is a general secondary care district hospital. The questionnaire has been extensively used before, 
and includes questions on the following symptoms: upper abdominal pain, heartburn, 
regurgitation, abdominal rumbling, bloating, nausea, empty feeling in the stomach, early satiety, 
postprandial fullness and belching (17-20). Patients were asked to rate the severity of the 
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symptoms over the previous four weeks on a 7-point Likert scale (0=absent; 1=hardly any; 
2=mild; 3=moderate; 4=moderately severe; 5=severe and 6=very severe). A symptom was 
considered to be present if it received a score of 2 or more, and predominant if it was rated more 
severe than symptoms of other dyspepsia subgroups. Completed questionnaires were returned at 
endoscopy and processed with Teleform automatic scanning software version 6.0 (Cardiff 
Software inc.; Sunnyvale, CA, USA). All aspects of the protocol were approved by the regional 
Medical Ethical Committees. 
 
ENDOSCOPY 
 
According to common practice, all patients who underwent a routine diagnostic upper 
gastrointestinal endoscopy were asked to stop using acid-suppressive medication 2 weeks prior to 
endoscopy. Endoscopic diagnosis was entered into a database. Patients were categorized 
according to results of endoscopy: gastric or esophageal cancer, Barrett’s esophagus, reflux 
esophagitis, gastric or duodenal ulcer, other organic abnormalities (e.g. varices or fungal 
infection) and no organic disorder explaining symptoms. Patients who had undergone an 
endoscopy in the past six months before enrollment were excluded from further analysis. 
 
ROME I CRITERIA 
 
According to the Rome I criteria patients reporting pain in the upper abdomen or discomfort 
(e.g. abdominal rumbling, bloating, empty feeling, nausea, early satiety, postprandial fullness or 
belching) were defined as having functional dyspepsia. If any symptom of heartburn or 
regurgitation was present, patients were believed to have GERD, and therefore could not have 
functional dyspepsia according to the Rome I criteria (9). 
 
ROME II CRITERIA 
 
Patients were divided in subgroups according to predominant (most severe) symptom, as defined 
by the Rome II criteria: ulcer-like if pain in the upper abdomen was scored higher than any other 
symptom, dysmotility-like if at least one non-painful sensation was the predominant symptom 
(abdominal rumbling, bloating, empty feeling in the stomach, nausea, early satiety, postprandial 
fullness or belching) and non-specific if symptoms did not fulfill ulcer-like or dysmotility-like 
dyspepsia criteria. If heartburn or regurgitation was predominant, thus rated more severe than 
any other symptom, patients were classified as having non-erosive reflux disease (21).  
 
ROME III CRITERIA 
 
If heartburn was the only symptom, patients were not regarded as having dyspepsia. The rest of 
the patients were divided into the two conditions defined in the Rome III criteria: postprandial 
distress syndrome (PDS) and epigastric pain syndrome (EPS). The first was diagnosed if patients 
reported to have postprandial fullness and/or early satiety. The latter was considered to be 
present if patients reported pain in the upper abdomen, not relieved by defecation (22).  
 
STATISTICAL ANALYSIS 
 
Analysis was performed with SAS statistical software, version 8.2. Data were summarized using 
descriptive statistics.  
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RESULTS 
 
A total of 1301 consecutive patients underwent a first endoscopy during the study period. Of 
these, 10 patients (0.8%) were under the age of 18 and were excluded from further analysis. Of 
the remaining patients, 8 (0.6%) had gastric or esophageal cancer, 65 (5%) had Barrett’s 
esophagus, 113 (8.8%) had a gastric or duodenal ulcer, 189 (14.6%) had reflux esophagitis and 64 
(5%) had another organic abnormality, such as esophageal varices, large hiatic hernia or fungal 
infection. Some patients had multiple diagnoses. 
 
Nine-hundred and twelve patients had no macroscopic abnormality at endoscopy that might have 
explained their symptoms. Frequencies of various symptoms among these patients are reported 
in table 1.  
 
Table 1: Patient characteristics and symptoms reported (N=912). 
  
Mean age ±SD 56±15 
 N (%) 
Male gender 420 (46) 
Upper abdominal pain 345 (38) 
Heartburn 304 (33) 
Regurgitation 316 (35) 
Abdominal rumbling 495 (54) 
Bloating 475 (52) 
Empty feeling in the stomach 216 (24) 
Nausea 259 (28) 
Early satiety 221 (24) 
Postprandial fullness 359 (39) 
Belching  395 (43) 
 
Using the Rome I, II, and III criteria, respectively 371 (41%), 735 (81%), and 551 (60%) of these 
patients had functional dyspepsia. Only 25% of patients had functional dyspepsia according to all 
3 Rome criteria, while 15% of patients with a normal endoscopy did not fit any of the Rome 
criteria. Functional dyspepsia according to the Rome II and Rome III criteria showed the greatest 
overlap: 57% of all patients was classified as having functional dyspepsia (figure 1).  
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Figure 1: All investigated dyspeptic patients (N=912) having functional dyspepsia according to 
the respective Rome criteria. 
 
 
Ulcer-like, dysmotility-like and non-specific functional dyspepsia, as classified by the Rome II 
criteria, were present in 5%, 48%, and 27% of all patients respectively. All patients with 
functional dyspepsia according to the Rome I criteria, also had functional dyspepsia according to 
the Rome II criteria. Respectively 3%, 29%, and 8% of all patients with functional dyspepsia 
according to the Rome I criteria had ulcer-like, dysmotility-like, or non-specific dyspepsia (figure 
2).  
 
Figure 2: All patients classified into subgroups according to the Rome II (outer ring) and the 
Rome I (inner ring) criteria. 
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The overlap between the Rome II and Rome III criteria was somewhat more complex (table 2). 
Forty-four percent and 42% of the patients respectively had epigastric pain syndrome (EPS) and 
postprandial distress syndrome (PDS) according to the Rome III criteria, while 26% of all 
patients had both conditions and 40% was not classified at all. EPS is thought to correspond with 
the ulcer-like subgroup from the Rome II criteria (23). However, actual overlap was only 3%, 
while the other 2% of subjects with ulcer-like dyspepsia overlapped with both EPS and PDS. 
PDS, on the other hand, is thought to correspond with the dysmotility-like subgroup from the 
Rome II criteria, but only 13% of all subjects fulfilled both criteria, 11% had dysmotility-like 
dyspepsia, EPS and PDS, while 19% of patients had dysmotility-like dyspepsia but was not 
classified by the Rome III criteria at all. Finally, the Rome III criteria classified an additional 5% 
of subjects, that were not classified using the Rome II criteria, while 24% of subjects was 
classified only by the latter. 
 
 
Table 2: Percentages of all patients (N=912) with functional dyspepsia according to the Rome II and 
Rome III criteria, divided by subgroups and overlap. 
 PDS alone (16%) 
N(%) 
EPS alone (18%)
N(%) 
PDS and EPS (26%) 
N(%) 
 No Rome III (40%) 
N(%) 
Ulcer-like 0 27 (3) 18 (2)  3 (0) 
Dysmotility-like 121 (13) 47 (5) 96 (11)  177 (19) 
Non-specific 19 (2) 72 (8) 110 (12)  45 (5) 
      
No Rome II 6 (1) 18 (2) 17 (2)  136 (15) 
PDS= Postprandial distress syndrome; EPS= Epigastric pain syndrome 
 
DISCUSSION 
 
Several attempts have been made to classify patients with upper gastrointestinal symptoms 
without an organic disorder underlying symptoms. However, results of this study show once 
again that small adjustments in the definition of functional dyspepsia and subgroups, as applied in 
the consecutive Rome criteria, lead to major fluctuations in the proportion of patients being 
diagnosed with functional dyspepsia. Especially the most recent Rome III criteria, which leave a 
large proportion of patients with endoscopy negative dyspepsia without diagnosis. Furthermore, 
from the patients that do have functional dyspepsia according to these criteria, the majority turns 
out to have both newly defined syndromes EPS and PDS. 
 
A major controversial issue is the potential overlap that may exist between functional dyspepsia 
and gastroesophageal reflux disease (GERD). Adjustments in the consecutive Rome criteria on 
how patients with heartburn should be classified caused the larger part the observed shifts in 
number of patients with functional dyspepsia. Excluding all patients with any heartburn or 
regurgitation from the functional dyspepsia diagnosis does not seem realistic, although presence 
of heartburn is a predictor of response to treatment with an anti-secretory agent (24). These 
symptoms should rather be regarded as part of the dyspeptic symptoms complex. 
 
Classification of disorders is important, as it facilitates uniformity in collection and analysis of 
research data and their comparison within populations over time and between populations at the 
same point in time. However, the applicability of a symptoms-based classification system to reach 
these goals has proven to be difficult in functional dyspepsia. When developing its Family of 
International Classifications, the World Health Organization (WHO) has set several conditions 
that a classification system should fulfill in order to be useful (25): 
 
CLASSIFICATION SHOULD BE BASED ON SOUND SCIENTIFIC AND TAXONOMIC PRINCIPLES. 
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Changes from the Rome II to Rome III criteria are based on expert opinions, backed by reviews 
of the literature. During the past years, symptoms, or symptom clusters have been identified that 
may be representative of specific disorders or subgroups (26). On the other hand, there is 
substantial evidence demonstrating that there are problems in using symptoms based diagnosis to 
subcategorize functional dyspepsia because of symptom overlap, changes in symptom 
presentation over time, and their poor predictive ability of response to treatment (27,28). 
 
CLASSIFICATION SHOULD BE CULTURALLY APPROPRIATE AND INTERNATIONALLY APPLICABLE. 
 
There are only few studies investigating the prevalence of functional dyspepsia among various 
ethnical groups. The little data available show that classification as it stands now, cannot be 
extrapolated to other cultures indiscriminately (29,30). Furthermore, symptom perception and 
definition, as well as patient behavior is subject to ethnical, psychological and demographical 
influences (31,32). None of the Rome criteria has considered these cultural and ethnical 
differences.  
 
IT SHOULD FOCUS ON THE MULTI-DIMENSIONAL ASPECTS OF HEALTH. 
 
It has been known that patients with functional dyspepsia have an impaired health-related quality 
of life (HRQL) and psychological distress is reported more often in comparison to healthy 
controls (33,34). Several studies have shown that HRQL and psychological distress are related to 
symptom severity, rather than to the reassurance of having a diagnosis, or knowing that there is 
no serious illness underlying symptoms (35-37). Since the Rome criteria do not contribute to a 
better management of patients in daily practice, these aspects of functional dyspepsia are unlikely 
to improve.  
 
IT SHOULD MEET THE NEEDS OF ITS DIFFERENT AND VARIED USER.  
 
Defining symptom complexes can be reassuring for patients and it may help physicians in making 
more general decisions. Well defined diagnostic criteria encourage physicians to make a positive 
diagnosis of functional dyspepsia instead of diagnosing by exclusion and may prevent ordering 
unnecessary diagnostic tests. However, terminology also causes confusion; the term dyspepsia is 
poorly understood by patients (38), and also many physicians are not familiar with the exact 
meaning of the term and do not use the complicated Rome criteria (39,40). In addition, 
subdivision into subgroups has no implications for treatment or prognosis. Although a small part 
of patients with abdominal pain seems to benefit from acid suppressive therapy (13), this is 
already therapy of first choice in all patients presenting with dyspepsia, and therefore of little 
relevance for patients and their treating physicians. 
For researchers there is a benefit in using the Rome criteria as they allow studies of patients with 
defined in- and exclusion criteria. This is useful for randomized controlled treatment trials, and 
allows for comparisons among different populations studied in different countries. However, 
application of strict criteria may hamper external validity of the study results, as the characteristics 
of the patients included in research tend to differ from the average patient seen in clinical 
practice, especially in primary care. 
 
CLASSIFICATION SHOULD ENABLE DERIVATION OF SUMMARY HEALTH MEASURES. 
 
An important aim of classification is to be able to gather epidemiological data for future 
treatment, prognosis or diagnosis. Our data demonstrate that a large proportion of patients with 
upper abdominal symptoms and no organic abnormality at endoscopy, is not classifiable 
according to the current criteria. Normally in clinical practice initial treatment will be primarily 
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aimed at use of acid suppressive therapy, as few other therapies, including prokinetic agents, have 
demonstrated equivocally that they are effective. Therefore, a discrimination between acid-related 
disorders and non-acid-related disorders, as is commonly used in clinical practice, would be more 
logical and appropriate (13,41,42).  
 
CLASSIFICATION SHOULD PROVIDE A PLATFORM FOR USERS AND DEVELOPERS. 
 
So far, not all groups with an interest in diagnostic criteria participate in the development process 
of the Rome criteria. Primary care physicians all over the world treat more than 90% of the 
patients with dyspepsia, taking into account differences in prognosis, background and culture. 
Their contribution could help to overcome some of the previously discussed drawbacks of the 
Rome criteria, and improve their applicability in daily clinical practice.  
 
Since endoscopic findings may be masked by prior treatment, patients in The Netherlands are 
instructed to discontinue acid suppressive medication 2 weeks prior to endoscopy. This period is 
insufficient to allow all ulcers and oesophagitis to relapse. It is also possible that a small 
proportion of patients did not discontinue their medication during endoscopy, which masked 
organic abnormalities. However, this was probably a small proportion of patients and considering 
the size of the study population, it is unlikely that this has influenced results. Furthermore, we did 
not have the referral indications to our disposal. Although it was shown that referral indications 
are not associated with endoscopic findings (43), it is likely that a small number of patients was 
referred to rule out celiac disease, or to investigate iron deficiency or anemia. Finally, all Rome 
criteria include a time frame in their definition of functional dyspepsia. In this study, patients 
were asked to rate their dyspeptic symptoms over the past 4 weeks before endoscopy. Although 
this might be a weakness of a retrospective analysis of this kind, it is fare to assume that 
symptoms have persisted for at least some months, before patients are referred for an endoscopy 
by their GP.  
 
It has to be considered that the Rome criteria are the product of an evolving process, leading to 
better and more workable classifications. However, the results of this study demonstrate that the 
Rome symptoms based classification systems for functional dyspepsia do not provide an easily 
applicable system that is useful in clinical practice. Especially the current Rome III criteria, which 
leave a large proportion of patients with a negative endoscopy without diagnosis, and the 
majority of the remaining patients fit the criteria for both newly defined syndromes. In daily 
clinical practice, acid-suppressive therapy is treatment of first choice in patients presenting with 
dyspepsia, and classification of patients is primarily based on response to this treatment. It looks 
like, in the light of the ambition of creating more clarity and oversight, the Rome III criteria have 
taken the wrong road: instead of improving compliance with the WHO basic conditions for 
diagnostic classification systems the updated criteria seem to divert further from daily clinical 
practice. 
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UPPER GASTROINTESTINAL ENDOSCOPY DOES NOT 
REASSURE PATIENTS WITH FUNCTIONAL DYSPEPSIA. 
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Background & Aim: Upper gastrointestinal endoscopy in patients with functional dyspepsia is 
often performed merely to reassure patients that symptoms are not due to serious pathology. The 
aim of this study was to compare anxiety, depression and health related quality of life as a proxy 
values for reassurance in patients with functional dyspepsia before and after upper 
gastrointestinal endoscopy. 
Patients and methods: Consecutive patients referred for endoscopy to the hospital between February 
2002 and February 2004 were included. They were asked to score anxiety and depression on the 
Hospital Anxiety and Depression Scale, health related quality of life on the EuroQol-5D and 
general experienced health on a Visual Analogue Scale, two weeks prior to endoscopy and again 
one month afterwards.  
Results: A total of 420 patients was included, 42% of whom where found to have an organic 
abnormality of some sort at upper gastrointestinal endoscopy. Neither the anxiety nor the 
depression scores were significantly different before and after endoscopy, either in patients with 
organic abnormalities at endoscopy or in those without. The general impression of health did not 
change after endoscopy either: organic 62.7±27.4 vs 64.9±24.2: p=0.28; functional 61.0±27.9 vs 
62.8±27.2: p=0.39. Only patients who had organic abnormalities reported a slightly improved 
quality of life one month after endoscopy: 0.74±0.15 vs 0.78±0.12: p<0.01. 
Conclusion: In patients with functional dyspepsia, upper gastrointestinal endoscopy does not 
improve psychological well being or health related quality of life. Considering the invasiveness, 
cost and potential harm associated with endoscopy, careful consideration should be given to 
whether this procedure should be carried out merely  for the sake of the patient’s ‘peace of mind’.  
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INTRODUCTION 
 
Functional dyspepsia - defined as the presence of persistent upper gastrointestinal symptoms 
without evidence of an organic disease that is likely to explain these symptoms – continues to be 
an important clinical problem. In general, treatment aims at gastric acid inhibition, but in most 
patients this is insufficient and symptoms persist (1-3). In these patients, often upper 
gastrointestinal endoscopy is performed to exclude serious pathology of the proximal gut, 
thereby providing reassurance to the physician and, in particular, to the patient (4).  
 
Extensive research has been done on the psychological aspects of functional gastrointestinal 
diseases. In a study by Quadri and Vakil, it was shown that health-related anxiety improves after 
open-access endoscopy in patients with high to moderate anxiety at baseline (5). Other studies 
have shown that patients with FUNCTIONAL DYSPEPSIA are more anxious and depressed in 
comparison to healthy controls or patients in whom the symptoms have an organic cause (6-11), 
and that health related quality of life (HRQL) is impaired in patients with functional dyspepsia in 
comparison with healthy control individuals and patients with other chronic disorders, such as 
asthma (12-15).  
 
In contrast, we demonstrated in a recent study that there is no difference in the level of anxiety or 
depression between patients with and without an organic cause of their symptoms before 
gastrointestinal endoscopy (16). Attempts have been made to quantify the effect of a negative 
endoscopy on HRQL (17) and a few studies have concluded that psychological well-being and 
HRQL improve with the improvement of symptoms (12,18). On the basis of these results it was 
concluded that psychological distress develops as a result of the disorder, rather than causing the 
symptoms itslef. Taking this into account, the policy of performing upper gastrointestinal 
endoscopy for reassurance of the patient appears illogical, since this diagnostic procedure is not 
likely to resolve symptoms and will therefore not contribute to the psychological well-being of 
the patient.  
 
The objective of this study was to investigate whether there are any differences in the level of 
psychological distress and HRQL, as proxy values for reassurance, before and after upper 
gastrointestinal endoscopy, between patients with and without an organic abnormality underlying 
the symptoms. 
 
METHODS  
 
SUBJECTS 
 
Between February 2002 and February 2004, consecutive patients referred for the first time for 
upper gastrointestinal endoscopy to the Canisius-Wilhelmina Hospital in Nijmegen, The 
Netherlands were included. This is a general secondary care district hospital. All patients were 
referred according to Dutch guidelines for general practitioners regarding the management of 
patients with dyspepsia. These guidelines state that an endoscopy is indicated if alarmsymptoms 
are present, when the general practitioner needs reassurance that there is no serious pathology 
underlying symptoms or if symptoms recur or persist after empirical treatment with a 
protonpump inhibitor and Helicobacter Pylori eradication treatment.  
 
It was not feasible to exclude in advance patient who had already undergone endoscopy during 
he previous six months. All patients referred for upper gastrointestinal endoscopy were therefore 
sent a questionnaire two weeks prior to their appointments. Patients were informed they should 
return the questionnaire only if they did not have a previous upper gastrointestinal endoscopy in 
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the previous six months. The questionnaire included enquiries on demographic information, the 
presence and severity of gastrointestinal symptoms, anxiety and depression and health related 
quality of life (HRQL). The questionnaire was repeated one month after the endoscopy, except 
for the questions concerning demographic data. All questionnaires were processed with Teleform 
automatic scanning software version 6.0 (Cardiff Software inc.; Sunnyvale, CA, USA). All aspects 
of the protocol were approved by the Medical Ethical Committees of Radboud University 
Nijmegen Medical Center and the Canisius-Wilhelmina Hospital both in Nijmegen, The 
Netherlands.  
 
ANXIETY AND DEPRESSION 
 
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS). This is a self-completed questionnaire that has been validated and can be used in a 
variety of clinical settings (19-21). It consists of 14 items and is divided into an anxiety and a 
depression sub-scale: each comprising 7 questions rated on a scale ranging 0 to 3, depending on 
the severity of the problem described in the question. This allows utilities to be calculated that 
indicate the individual’s degree of anxiety or depression. A sub-scale score below 8 is considered 
normal - i.e., no signs of anxiety or depression (22). Subjects were defined as having mild to 
severe anxiety or depression if they scored 8 or more on one of the respective subscales, although 
clinical signs might have been absent. Questions that were not filled out properly were not taken 
into further analysis.  
 
HEALTH RELATED QUALITY OF LIFE (HRQL) 
 
HRQL was assessed using the EuroQol-5D (EQ-5D) questionnaire, and generally experienced 
health in the previous weeks with a 100 mm Visual Analogue Scale (VAS). The EQ-5D is a 
widely used multi-attribute system suitable to determine health-state preferences (utilities). The 
EQ-5D classification describes health status according to five domains: mobility, self-care, daily 
activities, pain/discomfort and anxiety/depression at three levels, with 1 meaning no dysfunction 
at all and 3 meaning severe dysfunction. The validity and reliability of the questionnaire have 
been tested in a broad range of patient groups (23,24). The VAS is a line of standard length with 
the extremes of responses at each end. The scale ranges from 0 to 100, with 0 being the worst 
imaginable HRQL and 100 being the best. The patient is supposed to mark the line at an 
appropriate point, and the score is then obtained by measuring the distance from the beginning 
of the line to that point.  
 
SYMPTOM SCORE 
 
Patients were asked to complete a questionnaire with 32 items on gastrointestinal symptoms. The 
severity of the symptoms during the previous four weeks was rated on a 7-point Likert scale (0= 
absent and 6= very severe). A score of 2 or more was regarded as symptom presence.  
 
ENDOSCOPY 
 
Patients underwent a routine diagnostic upper gastrointestinal endoscopy, and outcomes were 
entered into a database. If necessary, histological data were obtained from biopsies taken during 
endoscopy. These biopsies were analysed by an experienced pathologist and results were entered 
into the same database. Results were retrieved from that database and patients were divided into 
groups according to their most prominent endoscopic outcome: i.e. carcinoma, gastric or 
duodenal ulcer, reflux-oesophagitis, other (e.g. esophageal varices, hiatic hernia or fungus), and 
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no organic abnormality underlying symptoms. When no endoscopic or histological explanation 
for symptoms could be found, patients were defined as having functional dyspepsia.  
 
Afterwards, patients were informed of the outcome of the endoscopy. If there was an organic 
abnormality, appropriate therapy was started; when there was no organic abnormality, patients 
were reassured that there was no severe pathology underlying symptoms.  
 
STATISTICAL ANALYSIS 
 
Statistical analysis was undertaken with SAS statistical software, version 8.0 (SAS Institute Inc, 
Minneapolis, MN, USA). Data at baseline were analysed using frequency tables and descriptive 
statistics. Patients with incomplete data were excluded from further analysis. A paired t-test was 
used to assess within-subject differences in the mean scores on anxiety, depression, HRQL and 
number of symptoms before and after endoscopy. The difference in severity of symptoms was 
assessed using Wilcoxon’s signed rank test. The influence of other variables on differences before 
and after endoscopy was assessed with linear regression models. Pearson’s chi-square analysis was 
used to assess differences in variables mentioned in table 1. Coffee and alcohol consumption was 
divided into two groups according to the median number of consumptions per week (20 and 7, 
respectively). A p-value <0.05 was considered statistically significant. Correlations between total 
HADS scores and symptom severity and number of symptoms were calculated using Spearman’s 
rank correlation. 
 
RESULTS  
 
A total of 1769 questionnaires was send and initially 932 were returned, 280 of which had to be 
excluded, as investigation of medical records showed that the patients had undergone an upper 
gastrointestinal endoscopy in the previous six months. The remaining 652 patients received the 
same questionnaire one month after endoscopy, and 515 were returned. Ninety five responders 
had to be excluded due to incomplete questionnaires. Complete response was available for 420 
patients of the initial 652 patients (64.4%; 197 (47%) men; mean age(SD) was 55(15) years).  
 
A total of 175 patients had an organic abnormality at endoscopy; 2% carcinoma, 7% gastric ulcer, 
5% duodenal ulcer, 55% reflux oesophagitis and 31% had another disorder (e.g. fungus, hiatic 
hernia). They were statistically significantly older, more often male and consumed more alcohol 
in comparison with patients without an organic abnormality (Table 1). A previous diagnostic 
intervention for upper gastrointestinal symptoms, other than endoscopy (i.e. X-ray, Helicobacter 
pylori test), was reported by 39% of the overall groups, and this was equally distributed between 
patients with and without an organic disorder at endoscopy (organic vs functional: 37% vs 31% 
for X-ray; p=0,19 and 12% vs 11% for H. pylori; p=0,76). Patients who reported having 
undergone a previous endoscopy (>6 months before the index endoscopy), were neither more 
anxious nor depressed at baseline than patients who did not (OR=1.0; 95%CI=0.6-1.5 and 
OR=1.3; 95%CI=0.8-2.0, respectively). None of the variables mentioned in table 1 were 
associated with a higher risk of anxiety, depression or decreased HRQL. 
 
When the mean scores on the Hospital Anxiety and Depression Scale (HADS) before and after 
endoscopy were compared, only patients with an organic abnormality at endoscopy showed an 
improvement in anxiety scores (Table 2). Using the cut-off point of a score of 8 or more per 
subscale, 31% of patients with an organic abnormality were anxious at baseline, in comparison 
with 28% after endoscopy (p=0.56), while 35% of patients with functional dyspepsia were 
anxious at baseline in comparison with 31% after endoscopy (p=0.33). Depression was present in 
27% of patients in both groups, before as well as after endoscopy. 
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Table 1: Demographics of the study population (N=420) 
 
Functional N=245 
N (%) 
Organic N=175 
N (%) p 
Male  104 (42) 93 (53) <0,05 
Previous endoscopy† 89 (36) 73 (42) 0,26 
Current smoking 34 (14) 31 (18) 0,28 
Alcohol use* 49 (20) 55 (31) <0,05 
Coffee consumption** 101 (41) 77 (44) 0,57 
Dutch nationality 219 (90) 162 (94) 0,16 
    
Mean age ±SD 53 ±15 57 ±14 0,01 
†Either upper, lower or sigmoidoscopy; *The median consumption was 7 units/week. Numbers showing are 
patients consuming more than 7 units/week; **The median consumption was 20 units/week. Percentages 
showing are patients consuming more than 20 units/week. 
 
 
 
 
Table 2: anxiety, depression, general health sensation and quality of life before (T0) and after 
(T1) upper gastrointestinal endoscopy: subdivision in organic and functional dyspepsia. 
 
n 
T0 
Mean ±SD 
T1 
Mean ±SD 
Mean difference 
(95%CI) p 
Anxiety      
Organic  169 5.8±3.8 5.3±4.0 0.57 (0.15-0.99) <0.01
Functional  228 6.3±4.4 6.2±4.4 0.21 (-0.18-0.61) 0.28 
Depression      
Organic 169 5.1±3.7 4.9±4.1 0.21 (-0.17-0.60) 0.28 
Functional 236 5.3±4.3 5.3±4.5 -0.03 (-0.40-0.34) 0.87 
VAS      
Organic 175 62.7±27.4 64.9±24.2 -2.16 (-6.06-1.74) 0.28 
Functional 245 61.0±27.9 62.8±27.2 -1.73 (-5.70-2.22) 0.39 
HRQL      
Organic 177 0.74±0.15 0.78±0.12 -0.04 (-0.05- -0.02) <0.01
Functional 236 0.72±0.17 0.72±0.18 0.00 (-0.02-0.02) 0.80 
No. of symptoms      
Organic 175 9.4±6.2 8.0±6.4 1.33 (0.72-1.93) <0.01
Functional 244 9.7±6.5 8.8±6.8 0.86 (0.30-1.42) <0.01
Severity of symptoms      
Organic 175 68.9±52.7 57.2±49.6 11.64 (3.79-19.49) <0.01
Functional 244 76.5±63.1 60.7±53.1 15.77 (7.87-23.66) <0.01
T0= two weeks before endoscopy; T1= one month after endoscopy; VAS= Visual Analogue Scale measuring 
health related quality of life in the past week; HRQL= Health Related Quality of life. 
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Generally experienced health, measured with a Visual Analogue Scale (VAS), did not improve 
over time in either group, nor were there any differences between the two groups before and 
after endoscopy. Patients with an organic abnormality at endoscopy reported a slight increase in 
health related quality of life (HRQL) after endoscopy: mean(SD) 0.74(0.15) at T0 vs 0.78(0.12) at 
T1; p<0.01. Both patients with and without an organic abnormality reported a statistically 
significant improvement in symptom severity scores and a reduction in the mean number of 
symptoms (Table 2). Linear regression analysis showed that none of the differences found in the 
outcomes listed in table 2 were influenced by gender, age, alcohol consumption or the presence 
of an organic disorder (Table 3). 
 
An increase in total number of symptoms (figure 1) was associated with an increase of mean 
scores on the HADS (correlation coefficient r=0,78; p<0,05). Figure 2 shows that, when dividing 
the total number of reported symptoms into subgroups, the proportion of patients reporting mild 
to severe anxiety and depression also increased with an increasing number of symptoms (figure 
2). However, an increase in symptom severity (figure 3) was not associated with an increase in the 
mean total anxiety and depression scores (r=0.17; p<0,05). 
 
 
 
 
Table 3: multivariable linear regression analysis of the influence of various variables on the 
differences of outcome variables between T0 and T1. 
 
Anxiety Depression VAS HRQL 
No. of 
symptoms 
Symptom 
severity 
 β R2 β R2 β R2 β R2 β R2 β R2
Organic abnormality 0.35 0.00 0.24 0.00 1.39 0.00 -0.04 0.02 0.46 0.00 -4.13 0.00
Gender 0.04 0.00 -0.28 0.00 -0.35 0.00 0.00 0.00 -0.01 0.00 -9.50 0.01
Age -0.02 0.02 -0.02 0.01 -0.11 0.01 0.00 0.00 -0.01 0.00 0.07 0.00
Alcohol usage 0.50 0.00 0.60 0.01 2.37 0.01 -0.04 0.02 -0.14 0.00 7.05 0.00
Complete model  0.03  0.03  0.02  0.04  0.01  0.01
Β=regression coefficient, representing the amount the dependent variable changes when the corresponding independent 
changes 1 unit; R2=total variance in the model explained by a specific variable. T0= two weeks before endoscopy; T1= 
one month after endoscopy; VAS= Visual Analogue Scale measuring health related quality of life in the past week; 
HRQL= Health Related Quality of life. 
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Figure 1: Correlation between total number of symptoms 
in the past 4 weeks and mean scores on the Hospital Anxiety 
and Depression Scale (HADS).
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Figure 3: Correlation between symptom severity over the past 4 weeks
and total score on the Hospital Anxiety and Depression Scale.
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Figure 2: Proportion of patients reporting mild to severe anxiety 
and depression on the hospital anxiety and depression scale.
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DISCUSSION  
 
Functional dyspepsia has often been associated with psychological distress (9). This study, 
including a large sample, investigated whether endoscopy improves psychological well-being in 
these patients. Although a reduction in severity of symptoms was observed, patients with 
functional dyspepsia do not seem to benefit from endoscopy. This finding is noteworthy, since it 
has often been stated that the main reason to perform endoscopy is to provide the patient with 
reassurance (25,26).  
 
Although patients with an organic abnormality at endoscopy reported a statistically significant 
improvement in health related quality of life (HRQL), the difference was so small (0,04 on a scale 
ranging from 0 to 1) that it has little or no clinical relevance. The improvement in symptom 
severity and the mean number of symptoms in these patients was also statistically significant, 
probably due to treatment received after endoscopy. Nevertheless, when the mean improvement 
in the number of symptoms is compared between patients with an organic abnormality and 
patients with functional dyspepsia, the difference in improvement is only 0,5 symptom. In 
addition, both groups still had a considerable number of symptoms after endoscopy, with an 
average of 8 or more. 
 
Using anxiety, depression and HRQL as proxy measures for reassurance, it was found that 
endoscopy does not reassure patients with upper abdominal symptoms. These results are in 
accordance with those very recently reported by Spiegel et al. This group investigated the effect 
of endoscopy in patients with another functional gastrointestinal disorder, irritable bowel 
0-  5    6-10 11-15 >16
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syndrome (IBS), and found no independent association between a negative colonoscopy and 
reassurance or an improved HRQL in these patients (27). 
 
Several other studies have investigated the role of endoscopy in patients with dyspepsia. In the 
past, it has been concluded that endoscopy is a cost-effective strategy in the management of 
patients presenting with dyspepsia (28). More recent studies have shown that ‘test-and-treat’ 
Helicobacter Pylori and/or empirical PPI treatment are as safe and efficient or even more 
effective than prompt endoscopy (29-32). The effect of an endoscopy on psychological well-
being was also investigated by Wiklund et al. They measured psychological well-being and HRQL 
one week before, and one week after endoscopy and found that endoscopy itself led to an 
improvement in both measures (25). Comparable results were found in a study in the USA 
including 60 subjects without an organic cause for symptoms, who were originally recruited for a 
double-blind, randomized clinical study to compare omeprazole with a placebo (26). Illness belief 
and worry about health were measured one week and immediately before endoscopy and 
immediately, 24 hours, one week, one month and a year after endoscopy, with patints being 
reassured that ‘there is nothing seriously wrong’. Results showed that immediately after 
endoscopy both illness belief and worry about health decreased, but normalized during follow-
up. In combination with the present results, this suggests that the initial improvement is only of 
brief duration and disappears a month after endoscopy. Both studies had some major limitations 
in study design that may have distorted results. In addition, the time between measurements was 
very short, so that the results may have been influenced by recognition bias. This casts doubt on 
the initial improvement in psychological well-being, which probably did not exist at all. 
 
Quadri and Vakil reported an improvement of 6 points on a scale ranging from 0 to 84 in health-
related anxiety among patients with high and moderate anxiety scores before endoscopy (5). They 
used a disease specific measure capable of detecting small alterations in health-related anxiety to 
assess the effect of open-access endoscopy. Although they reported a statistically significantly 
improvement, the clinical relevance of a 7% improvement on a disease specific scale is debatable. 
The present study was designed to assess clinically relevant changes in psychological well-being. 
The usefulness of generic measures is often criticized because of their limited possibility to detect 
small differences. We used generic measures to assess generally experienced anxiety, depression 
and HRQL, and combined these data with a symptom questionnaire. In this study this does not 
constitute a problem, and in fact a generic measure is preferable due to the advantage of 
generalizability to other populations (33). 
 
No correlation was found between symptom severity and the mean total HADS scores. This is in 
accordance with results described by Jones et al. (34). This study included 151 consecutive 
patients with functional dyspepsia and 90 healthy subjects, who scored their psychological 
distress and symptoms on validated questionnaires. We would endorse the authors’ conclusion 
that these correlations are too weak to conclude that there is a correlation between severity of 
symptoms and psychological distress.  
 
The response rate to the first questionnaire was quite low. This was due to the fact that all 
patients referred for upper gastrointestinal endoscopy received a questionnaire. Many patient may 
have considered themselves ineligible for participation in this trial because they had an upper 
gastrointestinal endoscopy in the previous six month, or had insufficient control of the Dutch 
language. These assumptions were confirmed by a random check of the medical records of over 
10% of the non-responders. The actual response rate for patients with a first upper 
gastrointestinal endoscopy was 64.4% and therefore response-bias can not be completely 
excluded. It is conceivable that patients with a psychiatric disorder are either more likely or 
unlikely than others to return the questionnaire. However, in general, the patients with and 
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without an organic abnormality had equal scores for anxiety and depression, HRQL and 
symptom severity. Therefore there is no reason to assume that response rates were different 
between the two groups. If any response bias is present, we would assume that this is equally 
distributed across both groups. 
 
In summary, although there appears to be an improvement in symptom severity after endoscopy, 
there is no clinically relevant improvement in the psychological well-being and HRQL of patients 
with upper gastrointestinal symptoms. In view of the invasiveness, cost and potential harm 
associated with upper gastrointestinal endoscopy, careful consideration should be given to 
whether this procedure should be carried out merely for the sake of the patient’s ‘for the peace of 
mind’. 
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Background & Aim: Antidepressants could be effective in the treatment of functional 
gastrointestinal disorders, through their anticholinergic and pain modulating effects. Previous 
studies with these drugs lacked sufficient power and were predominantly conducted in patients 
with the irritable bowel syndrome. This study aimed to assess the effectiveness of the serotonin 
and norepinephrine reuptake inhibitor venlafaxine in patients with functional dyspepsia. 
Methods: This was a multi-center, randomized, double-blind, placebo controlled trial. Participants 
had persistent dyspeptic symptoms and underwent upper gastrointestinal endoscopy in a 
secondary care hospital to exclude organic abnormalities. They were randomly assigned to receive 
8 weeks of treatment with either venlafaxine XR (2 weeks 75mg once daily, 4 weeks 150mg once 
daily, and 2 weeks 75mg once daily) or placebo. Symptoms, health related quality of life, anxiety 
and depression were assessed before, and at 4, 8, 12 and 20 weeks after inclusion. 
Results: 160 patients were randomized, 56% and 73% of participants completed treatment with 
respectively venlafaxine or placebo according to protocol. There was no difference in 
proportions of symptom-free patients after 8 weeks of treatment, nor at 20 weeks after inclusion, 
with venlafaxine in comparison to placebo (37% and 39% respectively; OR 0.8; 95%CI=0.3-2.1, 
and 42% and 41% respectively; OR 3.1; 95%CI=0.9-12.6). Per-protocol analysis did not reveal 
any differences between venlafaxine and placebo either (38% and 39% symptom-free 
respectively; OR 1.0; 95%CI=0.4-2.4 at 8 weeks). 
Conclusion: Treatment with the selective serotonin and norepinephrine reuptake inhibitor 
venlafaxine is not more effective than placebo in patients with functional dyspepsia.  
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INTRODUCTION 
 
Functional dyspepsia is defined as pain and/or discomfort centered in the upper abdomen 
without an organic disorder explaining symptoms (1). This symptom-complex constitutes a 
disorder frequently encountered in daily clinical practice of the general physician and the 
gastroenterologist; it is estimated that in 40-80% of patients referred for upper gastrointestinal 
endoscopy no organic disorder is found that might explain their symptoms(2,3). The problem in 
the management of functional dyspepsia is the high proportion of patients with recurring and 
persisting symptoms. Currently there is no therapy available that resolves or ameliorates 
symptoms in a substantial proportion of patients (4,5). 
 
The etiology of symptoms in patients with functional dyspepsia remains unclear, but there is a 
significant overlap with other functional gastrointestinal disorders such as the irritable bowel 
syndrome (IBS) (6,7). Whether symptoms originate in the brain, the nervous system, or the 
gastrointestinal tract remains the subject of a longstanding controversy. The current assumption 
is that it is a complex interplay of disturbed motility, visceral hypersensitivity and disturbed 
psychological responses that manifests as gastrointestinal symptoms (8,9).  
 
In several studies the role of tricyclic antidepressants (TCA) and selective serotonin reuptake 
inhibitors (SSRI) in IBS was investigated, and promising results were obtained. Unfortunately, 
most studies lacked sufficient power to draw firm conclusions (10,11). Few data are available on 
the role of psychotropic medication in dyspeptic symptoms. 
 
Despite this scanty evidence, many physicians regularly use antidepressants in daily clinical 
practice for patients with refractory dyspeptic symptoms; our group previously reported that 
about 25% of patients referred for an upper gastrointestinal endoscopy already uses psychotropic 
medication (12). It is obvious that a randomized placebo-controlled trial is needed to justify or 
dismiss such a treatment strategy. Therefore, this study was designed to investigate the effect of 
the selective serotonin and norepinephrine reuptake inhibitor venlafaxine on symptoms in 
patients with functional dyspepsia. 
 
METHODS 
 
SUBJECTS  
 
Patients were recruited in the period between June 2005 and March 2007. They underwent an 
upper gastrointestinal endoscopy in one of the five participating secondary-care centers. They 
were all referred for persisting dyspeptic symptoms (i.e. symptoms thought to originate from the 
upper gastrointestinal tract), but endoscopy did not reveal any organic abnormality that might 
have explained symptoms. All participant were over 18 years old, had no history of bipolar 
disorder, alcoholism, or eating disorders, reported no recent use of selective serotonin reuptake 
inhibitors or MAO inhibitors, were not pregnant or lactating at the time of inclusion nor planned 
to be in the near future, and did not have any other contraindications for venlafaxine use. All 
aspects of the protocol were approved by the Medical Ethical Committee of the Radboud 
University Nijmegen Medical Center, and the respective local ethical advisory boards of the other 
participating centers. 
 
TREATMENT AND MEASURES OF EFFECTIVENESS 
 
Before enrolment, patients were asked to quit all medication for gastrointestinal symptoms, such 
as acid suppressants and agents influencing gastrointestinal motility. After giving full informed 
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consent, patients were randomized to 8 weeks of treatment with either venlafaxine extended-
release (Efexor XR®, 75mg once daily in the first 2 weeks, 150mg once daily for the next 4 
weeks, and 75mg once daily in the last 2 weeks) or to identical placebo (figure 1).  
 
Number and severity of symptoms, anxiety and depression, and health-related quality of life were 
measured before the start of treatment, and at 4, 8, 12 and 20 weeks after inclusion. Participants 
who reported less than 2 symptoms were defined as being symptom-free. 
 
SYMPTOM SCORE 
 
Severity of gastrointestinal symptoms in the past 4 weeks was assessed using a valid self-report 
questionnaire. This symptom questionnaire contained items on demographics, lifestyle habits and 
current medication use, and has been extensively used before (13-16). The symptoms included: 
upper abdominal pain, heartburn, regurgitation, abdominal rumbling, bloating, nausea, empty 
feeling in the stomach, early satiety, postprandial fullness, and belching. Subjects were asked to 
rate the severity of gastrointestinal symptoms on a 7-point Likert scale (0=absent; 1=hardly any; 
2=mild; 3=moderate; 4=moderately severe; 5=severe and 6=very severe). A score of 2 or higher, 
was defined as presence of that particular symptom. 
 
ANXIETY AND DEPRESSION 
 
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS). This is a self-completed questionnaire that has been validated before, and can be used 
in a variety of clinical settings (17,18). It consists of 14 items and is divided in an anxiety and a 
depression sub-scale: each comprising 7 questions rated on a scale ranging 0 to 3, depending on 
the severity of the problem described in the question. This way utilities can be calculated that 
indicate the individuals degree of anxiety or depression. A sub-scale score below 8 is considered 
normal, i.e. no signs of anxiety or depression (19). Subjects had mild to severe anxiety or 
depression if they scored 8 or more on one of the respective subscales, although clinical signs 
might have been absent. Questionnaires that were not filled out properly were not taken into 
further analysis.  
 
HEALTH RELATED QUALITY OF LIFE (HRQL) 
 
HRQL was assessed using the EuroQol-5D (EQ-5D). The EQ-5D is a widely used multi-
attribute system suitable to determine health-state preferences (utilities). The EQ-5D 
classification describes health status according to five domains: mobility, self-care, daily activities, 
pain/discomfort and anxiety/depression on three levels, where 1 is no dysfunction at all and 3 is 
severe dysfunction. The validity and reliability of the questionnaire has been tested in a broad 
range of patient groups (20,21), and has been extensively used in patients with dyspepsia (22,23).  
 
DATA ANALYSIS 
 
Data at baseline were analyzed by means of frequency tables and descriptive statistics. 
Differences in baseline characteristics between men and women were analyzed with Student’s t-
test for continuous variables and with Pearson chi-squared test for metric variables, respectively. 
All patients who signed the informed consent form and started treatment were included in the 
intention-to-treat analysis, whereas the per protocol analysis only considered patients who 
completed treatment according to protocol. 
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Logistic regression analyses were performed to identify independent variables (i.e. age, gender, 
treatment, anxiety, depression and HRQL) associated with subjects reporting to be symptom-free 
(defined as scoring less than 2 symptoms on the symptom-questionnaire) at each measurement-
time. Odds ratio’s with 95% confidence intervals are denoted for dichotomous variables and beta 
with a p-value for continuous variables. Beta is the regression coefficient, representing the 
magnitude with which the dependent variable (being symptom-free) is influenced when the 
corresponding independent variable changes by one unit. Paired t-tests were used to assess the 
differences between scores at baseline and the consecutive measurement moments in symptom 
severity, mean number of symptoms, anxiety and depression, and HRQL. All statistical analyses 
were undertaken with SAS statistical software, version 8.2 (SAS Institute Inc, Minneapolis, MN, 
USA). 
 
Based on a pre-trial power calculation, in which it was expected that 50% of patients receiving 
venlafaxine and 30% of patients receiving placebo would be symptom-free after treatment, alpha 
being 0.05 and power set at 80%, it was estimated that at least 74 patients had to be included in 
each treatment arm.  
 
Randomization was done in blocks of six (3 venlafaxine and 3 placebo). Consecutive participants 
received the corresponding medication package. 
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RESULTS 
 
One hundred and sixty patients were randomized to receive either 8 weeks of treatment with 
venlafaxine (n=80) or identical placebo (n=80, figure 2). Of patients receiving venlafaxine 29 
(36%) were male compared to 36 (45%) of patients receiving placebo (p=0.3). mean age was 
similar; 52±15 (table 1). Respectively 45 (56%) and 58 (73%) of patients receiving venlafaxine 
and placebo completed treatment according to protocol (p=0.03). Of the first, the majority of 
those who prematurely ended treatment did so because of side-effects of venlafaxine (e.g. nausea, 
palpitations, sweating, sleeping disorders, dizziness, visual impairment). In the group receiving 
placebo the main reason to terminate treatment prematurely was the persistence of dyspeptic 
symptoms (figure 2).  
 
Table 1: Demographics and characteristics. 
 Venlafaxine 
N (%) 
Placebo 
N (%) 
 80 (50) 80 (50) 
Age   
< 30 years 8 (10) 10 (13) 
≥ 30 to 55 years 33 (41) 30 (37) 
> 55 years 39 (49) 40 (50) 
Male  29 (36) 36 (45) 
Most frequent symptoms   
Upper abdominal pain 59 (74) 62 (78) 
Bloating 66 (83) 56 (71) 
Belching 59 (74) 53 (67) 
Abdominal rumbling 54 (67) 47 (59) 
Early satiety 50 (63) 50 (63) 
 
INTENTION-TO-TREAT ANALYSIS 
 
127 patients returned the questionnaires 8 weeks after the beginning of treatment (80%). 
Intention-to-treat analysis showed that 37% of patients receiving venlafaxine compared to 39% 
of patients receiving placebo were symptom free after 8 weeks of treatment (OR 0.8; 
95%CI=0.3-2.1). At twelve weeks after inclusion these proportions were 29% and 39% 
respectively (OR 1.5; 95%CI=0.5-4.4). At 20 weeks after inclusion 42% of patients receiving 
venlafaxine and 41% of those receiving placebo were symptom-free (OR 3.1; 95%CI=0.9-12.6) 
(figure 3a). There was no improvement in individual symptoms at any point in time. 
 
The mean number of symptoms reported improved statistically significantly over time in all 
patients (paired differences with baseline scores 2.7; 95%CI=1.7-3.7 and 3.8; 95%CI=2.5-5.1 
after 8 and 20 weeks respectively with venlafaxine, and 1.8; 95%CI=1.2-2.4 and 3.1; 95%CI=2.3-
3.8 after 8 and 20 weeks respectively with placebo), as did symptom severity scores (paired 
differences with baseline score 7.8; 95%CI=5.2-10.4 after 8 weeks, and 10.2; 95%CI=6.9-13.5 
after 20 weeks with venlafaxine, and 5.5; 95%CI=3.6-7.4 after 8 weeks, and 9.4; 95%CI=6.9-12.0 
after 20 weeks with placebo). Depression scores improved statistically significantly at 12 and 20 
weeks after inclusion in comparison to scores at baseline in patients receiving venlafaxine (paired 
difference 0.9; 95%CI=0.1-1.7, and 1.3; 95%CI=0.3-2.3, respectively). Anxiety scores were only 
improved 20 weeks after inclusion in patients who received venlafaxine: paired difference 0.7; 
95%CI=0.1-1.3. Although differences are small, scores for health-related quality of life were 
statistically significantly better after 8 weeks of treatment and 20 weeks after inclusion in patients 
receiving venlafaxine (paired differences 0.06; 95%CI=0.01-0.12 and 0.08; 95%CI=0.02-0.15, 
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respectively). In patients receiving placebo this was only the case 12 weeks after inclusion (paired 
difference 0.05; 95%CI=0.02-0.08). At none of the measurement-times there was a statistically 
significant difference in mean symptom number, symptom severity, anxiety and depression 
scores, or HRQL scores between the two treatment arms (table 2). 
 
Figure 2: Flowchart, describing number of included patients and drop-out. 
 
 Enrolled N=160  
 Venlafaxine  Placebo  
     
Step 1 (2 weeks 1dd 75mg) N=80  N=80  
       
    
Persisting dyspeptic 
symptoms 4; Headache 1; 
Nausea 6; Palpitations 1; 
Visual impairment 1; 
Diarrhoea 1; Insomnia 2; 
Surgery unrelated to 
treatment 2; Unknown 2. 
  
 
  
Persisting dyspeptic 
symptoms 5; 
Headache:1; Nausea 1; 
Unknown 2. 
       
Step2 (4 weeks 1dd 2x75mg) N=60  N=71  
       
    Persisting dyspeptic 
symptoms 5; Nausea 1; 
Haziness 2; Fever 1; 
Headache 1; Hay fever and  
bronchitis 1. 
  
 
  
Persisting dyspeptic 
symptoms 4; Back pain 
1; Insomnia 1; Unknown 
1. 
       
Step 3 (2 weeks 1dd 75 mg) N=49  N=64  
       
    Moved away 1; Insomnia 1; 
terminal stage other disease 1; 
Unknown 1.   
 
  
Persisting dyspeptic 
symptoms: 4; Influenza 
1; Pneumonia 1. 
       
Completed  N=45  N=58  
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Figure 3a: Proportions of patients being symptom free (<2 symptoms) during treatment and 
follow-up: intention-to-treat analysis. 
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Figure 3b: proportions of patients being symptom free (<2 symptoms) during treatment and 
follow-up: per protocol analysis. 
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PREDICTORS OF OUTCOME 
 
Logistic regression analyses of all participants revealed that at 4 weeks after inclusion, only the 
absence of anxiety was associated with a decreased risk of subjects still reporting symptoms (OR 
0.83; 95%CI=0.67-1.0). Eight weeks after inclusion, at the end of treatment, the absence of 
anxiety, male gender and increasing scores on health-related quality of life are associated with 
being symptom-free (OR 0.84; 95%CI=0.71-0.99 for anxiety, OR 0.35; 95%CI=0.13-0.88 for 
male gender, and β=-5.0; p=0.01 for HRQL). At 12 and 20 weeks after inclusion only health-
related quality of life is associated with subjects being symptom-free (β=-12.9 and β=-18.1 
respectively; p<0.01 for both). There is no association between being symptom-free and 
treatment at any time. 
 
PER PROTOCOL ANALYSIS 
 
Of subjects who fulfilled treatment according to protocol 37% (venlafaxine) and 43% (placebo) 
were symptom-free after 8 weeks of treatment (OR 0.9; 95%CI=0.3-2.5). At 12 weeks after 
inclusion a respective 30% and 43% of patients was symptom-free (p=0.2). At 20 weeks after 
inclusion 43% was symptom-free in both treatment arms (OR 3.5; 95%CI=0.9-15.3) (figure 3b). 
In these subjects only health-related quality of life is statistically significantly associated with 
being symptom-free at 8 weeks after inclusion (β=-5.2; p=0.02), and at 12 and 20 weeks after 
inclusion (β=-12.8 and β= -17.9, respectively; p<0.01). 
 
Table 2: Paired differences in scores for various variables between T0 and consecutive follow-up 
times. 
  Baseline score 8 weeks 20 weeks 
Mean no. of symptoms P 6.0±2.7 3.9±3.1 3.4±2.9 
 V 6.9±3.2 4.5±3.3 4.3±3.3 
Δ (95%CI) 0.9 (-0.04-1.9) 0.6 (-0.5-1.8) 0.9 (-0.4-2.1) 
Symptom severity P 19±8 13±9 12±9 
 V 21±9 15±10 14±10 
 Δ (95%CI) 1.7 (-1.2-4.6) 1.9 (-1.6-5.5) 2.0 (-1.7-5.7) 
Anxiety score P 6.1±3.9 6.1±4.3 5.9±4.7 
 V 5.8±3.7 5.4±4.3 4.4±3.2 
 Δ (95%CI) 0.3 (-0.9-1.5) 0.7 (-0.9-2.3) 1.5 (-0.3-3.2) 
Depression score P 5.0±4.2 4.7±4.4 4.8±4.4 
 V 4.9±4.2 5.3±3.9 4.6±4.0 
 Δ (95%CI) 0.1 (-1.4-1.4) 0.5 (-1.0-2.1) 0.3 (-1.5-2.0) 
HRQL P 0.74±0.14 0.76±0.15 0.73±0.18 
 V 0.72±0.17 0.75±0.18 0.79±0.16 
 Δ (95%CI) 0.02 (-0.03-0.07) 0.01 (-0.05-0.07) 0.06(-0.01-0.13) 
P= placebo; V= venlafaxine. Ranges: number of symptoms 0-10; symptom severity 0-6 for each symptom; anxiety 0-
21; depression 0-21; HRQL= health-related quality of life 0-1. 
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DISCUSSION 
 
The results of this randomized, double blind and placebo controlled trial show that treatment 
with a selective serotonin and norepinephrine reuptake inhibitor is not more effective than 
placebo in patients with functional dyspepsia. Several previous studies have investigated the role 
of treatment with antidepressants in functional gastrointestinal disorders, mainly the irritable 
bowel syndrome (IBS). Results were predominantly in favor of antidepressants. Since symptoms 
of IBS and functional dyspepsia often overlap, it has been postulated that there is a common 
mechanism underlying these disorders (24,25). It is therefore reasonable to hypothesize that 
treatment with antidepressants might also be effective in patients with functional dyspepsia.  
 
In a recent meta-analysis, including all trials investigating the effect of antidepressants in IBS, it 
was concluded that the overall effect was positive. This observation supported the use of 
antidepressants in patients with IBS (26). However, it was also concluded that most studies were 
poorly designed and lacked sufficient power to draw firm conclusions. Similarly, a recent review 
identified 13 articles investigating the role of antidepressive and antianxiety agents in functional 
dyspepsia. Only 4 of these papers described blinded, randomized placebo controlled trials with 
acceptable outcome measures, investigating tricyclic antidepressants, selective serotonin reuptake 
inhibitors and a combination of anticholinergic and antianxiety agents. None of these trials 
included more than 50 subjects. Although meta-analysis of these studies showed that there was 
an overall positive effect of antidepressant/antianxiety drugs over placebo, the funnel-plot 
showed asymmetry which indicates publication bias (27). Still these results, and the lack of 
alternatives (28,29), have contributed to antidepressants being a common drug of choice in 
patients with unexplained, persisting dyspeptic symptoms.  
 
No study has previously investigated the effect of venlafaxine, which not only strongly inhibits 
the reuptake of serotonin, but also that of norepinephrine. Since the current results are in 
contradiction with some previous results, it might implicate that the dopaminergic action of 
venlafaxine overrules the positive effects obtained by agents just inhibiting serotonin reuptake. 
Nevertheless, the current results show that a combination of these characteristics is ineffective in 
patients with functional dyspepsia.  
 
The best way to measure outcomes in functional disorders has been subject of debate for a long 
time. For this study, being symptom free was defined as reporting less than two symptoms. This 
was chosen for several reasons: firstly it was aimed to define a clear, as objective as possible 
outcome; secondly, it is known that most patients report multiple symptoms; thirdly, symptoms 
tend to change over time, somebody presenting with predominantly pain might report 
predominantly bloating if asked after some time; fourthly, a very large proportion of the general 
(non consulting) population reports at least one gastrointestinal symptom if asked. To adjust for 
these phenomena, it was agreed that subjects with only one symptom were defined as symptom 
free. 
 
A reduction in total number of symptoms and symptom severity was observed, which started 
immediately after the beginning of treatment and continued even until 20 weeks after inclusion. 
This occurred in patients from both groups receiving either venlafaxine or receiving placebo, and 
there were no statistically significant differences between the two groups at any point in time. 
Considering this, and the fact that dyspeptic symptoms are known to disappear and recur over 
time (30,31), this is most probably the result of the natural course of the disease. A placebo effect 
of hospital visits and the knowledge of being in a clinical trial might also have contributed to 
symptom reduction. The observation that the presence or absence of symptoms is related to 
psychological factors and health-related quality of life, rather than treatment, is in concordance 
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with previous results (32). Recent trials investigating behavioral therapy in patients with 
functional gastrointestinal disorders have obtained promising results (33). Treatment should 
probably rather be aimed at giving these patients reassurance and reducing gastrointestinal 
symptoms by improving mental well-being (34).  
 
Inclusion of patients was dependent on their willingness to participate. As with every trial, it is 
possible that participators represent a distinct subset of patients. Their symptoms might be more 
severe than those of average patients with functional dyspepsia, or they might be more aware of 
their physical health and, as such, more keen on bodily sensations. Since subjects were equally 
randomized to each treatment arm, this has probably not influenced results. However, when 
extrapolating the results to an average population with functional dyspepsia, it should be 
considered that the true effect of antidepressants could be even less than in the currently 
investigated population.  
 
Although this trial initially included 80 participants in each treatment arm, only 45 and 58 patients 
completed treatment with respectively venlafaxine and placebo according to protocol. Dropout 
in the venlafaxine-arm was mainly due to symptoms related to treatment. In the placebo-group 
most patients stopped because of recurrent or persisting dyspeptic symptoms. Unfortunately it 
was not registered what proportion of patients used rescue medication, such as antacids and 
histamine2-receptor antagonists which are available over the counter in The Netherlands. The 
current observed difference in dropout rates implicates that, despite our overall results, there was 
a difference in symptom response and sensation between participants. Several studies have 
shown that the incidence of adverse drug events during treatment with venlafaxine extended-
release (dose range 75mg-225mg) is similar to that during treatment with established pure 
serotonin reuptake inhibitors (35,36). It is very well possible that subjects who prematurely quit 
venlafaxine are more sensitive to the effect of this drug, and it might be interesting to assess the 
effect of lower doses. Anyhow, a high dropout rate should be considered before the start of every 
trial and should be included in the pre-trial power calculation. 
 
Placebo-response is known to be high among patients with functional gastrointestinal disorders, 
as was also the case in the current study population (37). This makes it difficult to demonstrate a 
statistically significant difference between placebo and a therapeutic intervention. Large sample-
sizes are needed, and alternative study designs need to be considered. A cross-over design has 
been used in other trials (38). However, the natural course of symptoms in functional dyspepsia is 
very unstable over time and it is almost impossible to get subjects back to baseline scores before 
starting the second treatment intervention. In order to exclude placebo-responders, one could 
assign all participants to a few weeks of treatment with placebo before enrollment in the true 
study. Since this might not be ethical, an alternative approach would be to treat everybody with 
acid-inhibitors. This way both people with acid-related disorders, as well as placebo-responders 
would be identified and can be excluded from further participation in the trial. A more 
homogeneous studygroup would be created and the true effect of an intervention can be more 
properly assessed. 
 
In conclusion, a strong serotonin reuptake inhibitor, venlafaxine, is ineffective in patients with 
functional dyspepsia. Venlafaxine is distinct from other antidepressants in that it not only 
strongly inhibits reuptake of serotonin, but also of norepinephrine and dopamine. The exact 
influence of this last characteristic remains to be investigated.  
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The diversity of studies described in this thesis reflects the complexity of unexplained 
gastrointestinal symptoms. As mentioned in the introduction section, the name “functional 
dyspepsia” itself already raises questions and is subject to individual interpretation. Dyspepsia is 
not a disease in itself, rather it reflects a complex of symptoms thought to originate from the 
upper gastrointestinal tract. As such, terminology causes confusion; the term dyspepsia is poorly 
understood by patients (1), and also many physicians are not familiar with the exact meaning of 
the term (2,3). The additive ‘functional’ does not make things more clear since it suggests that 
this symptom complex has a deeper meaning, whereas it actually means that we just do not know 
what is going on. 
 
EPIDEMIOLOGY 
 
Virtually everybody suffers from upper gastrointestinal symptoms every once in a while. Yet, by 
far not everybody consults a physician with these symptoms (4,5). Attempts have been made to 
differentiate between these two groups of people; those who consult a physician for their upper 
gastrointestinal symptoms and those with more or less the same symptoms who do not. For this 
purpose, it is of importance to obtain insight in the prevalence of gastrointestinal symptoms 
among the general population.  
 
In the first part of this thesis a self-report questionnaire was used to assess the prevalence of 
gastrointestinal symptoms among a large representative sample of the general population. 
Response rates were low, as might be expected from a door-to-door mailing. This means that 
results should be interpreted with a certain caution: it is very well possible that people who suffer 
from gastrointestinal symptoms were more likely to fill out the questionnaire. Nevertheless, the 
included sample was representative for the Dutch population on many demographic parameters, 
and results are valuable because they show that gastrointestinal symptoms are very common 
among a non-specific Western population.  
 
In the same part of this thesis the current prevalence of specific findings at upper gastrointestinal 
endoscopy is compared to the prevalence of the same disorders in the early nineties. Within this 
timeframe, several factors associated with the development and/or treatment of upper 
gastrointestinal symptoms have changed: proton pump inhibitors and the eradication of 
Helicobacter pylori have been introduced in guidelines for the treatment of patients presenting with 
upper gastrointestinal symptoms, the usage of NSAIDS has increased, endoscopic technology has 
improved, the prevalence of overweight is steadily increasing, and lifestyle habits associated with 
this increase, such as smoking, diet and physical exercise, have altered. Although there can only 
be speculation on the exact influence on the prevalence of gastrointestinal disorders of all these 
individual factors, it is likely that the observed decreased prevalence of peptic ulcer disease is 
attributable to the policy on eradication of H. pylori. The observed increase in the prevalence of 
reflux oesophagitis over the past 15 years is most probably the result of the increasing 
bodyweight of the Dutch population (6-9).  
 
ETIOLOGY 
 
Although there are substantial differences between functional dyspepsia and ‘the other’ 
functional gastrointestinal disorder, the irritable bowel syndrome (IBS), these two disorders also 
show great overlap. Up until now there is no general consensus on whether these two symptom 
complexes should be regarded as different disorders or are in fact one and the same. In most 
scientific studies they are viewed as separate entities and most research is conducted in patients 
with IBS. It is generally assumed that the brain-gut axis plays an important role in symptom 
generation (10,11). 
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Mood is an important aspect of the brain-gut axis. It has previously been shown that both 
patients with functional dyspepsia as well as patients with IBS have more psychological distress, 
score worse on health-related quality of life and more often report a history of abuse than healthy 
control subjects (12-14). It remains unknown, however, what is the primary factor and what is a 
secondary consequence. In part II of this thesis, a large population referred for upper 
gastrointestinal endoscopy was asked to fill out a self-report questionnaire on anxiety and 
depression. Data on endoscopic findings were obtained from medical files, and it was shown that 
there is no difference in anxiety and depression between patients with an organic disorder 
underlying symptoms and patients with functional dyspepsia. These results indicate that high 
anxiety and depression scores among patients with functional gastrointestinal symptoms are the 
result of symptoms, rather than a cause of symptoms.  
 
Another important factor in the brain-gut axis is serotonin. This neurotransmitter is present in 
the brain where it influences mood, but the majority is located in the gut where it facilitates 
gastrointestinal motility, sensibility and excretion (15). Serotonergic action is terminated by the 
serotonin transporter protein (SERT-P), which facilitates reuptake from the synaptic cleft. 
Activity of SERT-P has been associated with IBS-like symptoms in animal experiments (16,17). 
As such, a functional polymorphism in the gene encoding for SERT-P activity was marked a 
candidate gene involved in symptom generation in IBS. Several studies have been conducted in 
order to identify an association between this polymorphism and IBS, with contradicting results. 
This thesis contains a meta-analysis of all these studies which shows that there is no such 
association, neither with IBS, nor with any of the IBS subtypes. This means that the influence 
serotonin has on symptom development in IBS is probably merely associated with synthesis and 
release upon stimulation, rather than hereditary functioning of its reuptake protein. 
 
DIAGNOSIS 
 
The diagnosis functional dyspepsia is made by exclusion. It implies that diagnostic evaluation has 
been performed, including upper GI endoscopy, and that organic abnormalities have been 
excluded. Considering the invasiveness of this procedure, it is logical that several attempts have 
been made to identify factors or characteristics that would facilitate a positive diagnosis of 
functional dyspepsia, or that at least would identify patients most likely to have no abnormalities 
at endoscopy beforehand.  
 
It seems natural to use symptom type or severity to categorize patients, as this is what patients 
present with to their physician. Attempts have been made to define symptom complexes that 
would be indicative for an underlying disorder, such as peptic ulcer disease or gastro-oesophageal 
cancer. Furthermore, several symptom based classification systems have been proposed, of which 
the consecutive Rome criteria are the most well-known, that identify subgroups of patients with 
functional dyspepsia (18-20). Recent reports, however, have shown that dyspeptic symptoms are 
very atypical, unstable over time, and are not indicative for underlying disorders (21-23). In the 
third part of this thesis, data on symptoms reported by a large cohort of patients without 
endoscopic abnormalities were analyzed. It is shown that symptom-based classification systems 
are not useful and that small adjustments in definitions can have a major influence on whether 
certain patients are diagnosed with functional dyspepsia, or not. Furthermore, reasons for referral 
for an upper GI endoscopy, as provided by the general physician, were evaluated. It also became 
clear that the indication for endoscopy did not have any additive value on the chance of finding 
an organic abnormality above what one might expect from the prevalence of that disorder. 
Finally, alexithymia, a character trait that would identify patients that have difficulty to distinguish 
between emotions and bodily sensations, was analyzed. It was hypothesized that persons with 
this trait would be more prone to functional GI disorders, but no association could be shown. 
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These results indicate that although symptoms are what patients present with, they are useless for 
categorizing patients or to determine a treatment strategy. Researchers and clinicians should 
rather make an effort out of trying to identify objective parameters, in order to facilitate a 
positive diagnosis of functional dyspepsia and to define subgroups of patients for scientific 
research. 
 
TREATMENT  
 
About 90% of patients with functional dyspepsia is treated by the general physician. There is, 
however, no universally accepted therapeutic approach, and many patients respond different to 
available therapies. The current assumption is that symptoms of functional dyspepsia are a 
manifestation of a complex interplay of disturbed motility, visceral hypersensitivity and disturbed 
psychological responses. As a result, several studies have investigated the effect of drugs 
influencing one or more of these mechanisms, such as antidepressants. Results were 
contradicting, though predominantly positive, and the quality of trials poor. Nevertheless, this 
has caused antidepressants to be treatment of choice in daily clinical practice for patients with 
uncomprehendable gastrointestinal symptoms.  
 
The fourth part of this thesis describes a randomized placebo controlled trial investigating the 
effect of a selective serotonin and norepinephrine reuptake inhibitor, venlafaxine, in patients with 
functional dyspepsia. It is shown that this antidepressant is not more effective than placebo. 
However, the lack of effect of venlafaxine does not mean that other antidepressants are 
ineffective as well. It is very well possible that agents that do not inhibit norepinephrine, tricyclic 
antidepressants, or even venlafaxine in another dose are effective in the treatment of functional 
dyspepsia. After all, despite small sample sizes and poor design, several studies have shown a 
positive effect of some of these agents. The positive effect is often thought to be through a 
serotonergic effect on the GI tract, rather than an effect on mood. Low doses were used in the 
trial with venlafaxine, but the high number of dropouts due to side effects might indicate that we 
are dealing with a very sensitive group of patients. Ironically these might just be the patients who 
could benefit most from this type of agents, since they obviously show a response but in an 
exaggerated manner. 
 
In clinical practice, upper gastrointestinal endoscopy is often performed to provide reassurance 
that there is no severe pathology underlying symptoms. In the fourth part of this thesis it is also 
shown that after upper gastrointestinal endoscopy symptom severity and the number of 
symptoms improve, but that this is the case in patients with and without an organic disorder 
underlying symptoms. More importantly, using anxiety and depression as a proxy for mental well-
being, it is shown that a ‘negative’ endoscopy does not reassure patients. Performing this 
procedure ‘for the peace of mind’ of the patient should be carefully considered. These results 
strengthen the assumption that psychological distress is a result of symptoms, rather than causes 
them.  
 
HOW FUNCTIONAL IS DYSPEPSIA? 
 
Unfortunately this thesis does not hold the answer to that question. It has, however, contributed 
to further unravel the mechanisms underlying the complicated symptom complex of dyspepsia.  
 
The functionality of dyspeptic symptoms in the sense that it is unclear what causes these 
symptoms has been addressed. It was shown that psychological distress is most likely the result 
of symptoms, rather than the cause, a genetic association with the SERT-P gene seems to be very 
 114
unlikely, and these patients obviously do not respond to treatment with a selective serotonin and 
norepinephrine reuptake inhibitor.  
Regarding the functionality of dyspeptic symptoms in the true meaning of the word, it was 
shown that neither a specific character trait, nor the reasons for referral as provided by the 
general physician could identify patients without an organic abnormality at endoscopy 
beforehand. Furthermore, symptoms have proven to be useless for identifying patients with 
functional dyspepsia or to classify them into subcategories.  
 
The current situation is that physicians have to deal with a large heterogeneous group of patients, 
presenting with a broad range of symptoms, that respond insufficiently to available therapy. It is 
known that a small proportion of patients with functional dyspepsia responds well to acid-
inhibiting therapy or Helicobacter pylori eradication. When determining a treatment strategy, 
clinicians should try to focus on these objective parameters, rather than base their decisions on 
type and severity of symptoms. The studies in this thesis have shown that this is unreliable, and 
may lead to unnecessary diagnostic interventions. There is no legitimate reason to divide patients 
into subgroups, and therefore scientific research should approach this group as a whole without 
excluding certain individuals from clinical trials beforehand. It might be useful though, to 
consider alternative study designs which include an initial run-in period with a protonpump 
inhibitor in order to exclude patients with acid-related disorders and to reduce placebo response.  
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SUMMARY 
 
Functional dyspepsia is, after the irritable bowel syndrome, the second most prevalent functional 
gastrointestinal disorder. Because of similarities and symptom overlap, it is also conceivable that 
they are actually one and the same disorder. This thesis handles on the functionality of 
gastrointestinal symptoms thought to originate in the upper gastrointestinal tract, for which no 
organic origin can be identified, and that do not respond satisfactory to available treatment.  
 
Epidemiology: A questionnaire was spread door-to-door and it was observed that gastrointestinal 
symptoms are a very common phenomenon among a representative sample of the general 
population (chapter 1). It was also shown that over the years, while risk factors and behavioural 
patterns have changed, the prevalence of various abdominal abnormalities observed at upper 
gastrointestinal endoscopy has altered: peptic ulcer disease became less prevalent, whereas the 
prevalence of reflux oesophagitis has increased (chapter 2).  
Etiology: Disturbed mood is often thought to underlie inexplicable gastrointestinal symptoms, and 
previous studies reported that patients with functional dyspepsia are more anxious and depressed 
than healthy controls. In this thesis however, a comparison of anxiety and depression between 
two large groups of patients with and without an organic disorder underlying symptoms revealed 
no difference (chapter 3). Furthermore, serotonin, a neurotransmitter involved with both mood 
as well as gut motility and sensibility, has often been thought to play a role in functional symptom 
generation. Several studies investigated the effect of a functional polymorphism in its reuptake 
protein, terminating its action, in patients with the irritable bowel syndrome with diverging 
results. Meta-analysis of these studies showed that overall there is no association (chapter 4). 
Diagnosis: Efforts have been made to define characteristics that would identify patients more or 
less likely to have a certain disorder underlying symptoms. Guidelines for general physicians 
describe a set of criteria for patients to be referred for an endoscopy. In this thesis it is shown 
that reasons for referral as indicated by general physicians do not have any additive value of 
finding an organic abnormality underlying symptoms over what might be expected from the 
prevalence of disorders (chapter 5). Alexithymia, a character trait that would identify patients that 
have difficulty to distinguish between emotions and bodily sensations, was analysed. It was 
hypothesized that persons with this trait would be more prone to functional GI disorders, but no 
association could be shown (chapter 6). Finally, symptoms, the most obvious and logical 
measures to categorize patients, were analysed. Many symptom-based classification systems have 
been proposed, of which the Rome criteria are the most well known. It was shown that 
symptom-based classification systems are not useful and that small adjustments in definitions can 
have a major influence on whether certain patients are diagnosed with functional dyspepsia, or 
not (chapter 7). 
Treatment: In order to reassure both the physician as well as the patient that there is no severe 
pathology underlying symptoms, upper gastrointestinal endoscopy is often performed in patients 
with functional dyspeptic symptoms. Using anxiety and depression as a proxy for mental well-
being, it was shown that a ‘negative’ endoscopy does not reassure patients (chapter 8). Because of 
the suspected complex role of the brain-gut axis underlying symptoms, several studies 
investigated the influence of drugs influencing this mechanism. The effect of antidepressants was 
predominantly positive in patients with the irritable bowel syndrome. In this thesis it is shown 
that venlafaxine, a serotonin and norepinephrine reuptake inhibitor, is not effective in patients 
with functional dyspepsia.  
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SAMENVATTING 
 
Na het prikkelbare darm syndroom is functionele dyspepsie de meest voorkomende functionele 
maag- darmaandoening. Door de overeenkomsten tussen deze twee aandoeningen is het ook 
denkbaar dat het eigenlijk om dezelfde aandoening gaat. Dit proefschrift gaat over de 
functionaliteit van gastrointestinale klachten waarvan aangenomen wordt dat ze in de bovenbuik 
ontstaan, waarvoor geen organische verklaring te vinden is en die niet effectief te behandelen zijn. 
 
Epidemiologie: Een vragenlijst over buikklachten werd huis-aan-huis verspreid en het bleek dat 
deze symptomen veel voorkomen in een representatieve steekproef van de algemene bevolking 
(hoofdstuk 1). Verder werd aangetoond dat gedurende de afgelopen 10-15 jaar, waarin 
risicofactoren en gedragspatronen aanzienlijk zijn veranderd, er een verschuiving heeft 
plaatsgevonden in het vóórkomen van bepaalde bovenbuikaandoeningen zoals gevonden bij 
gastroscopie. Zo werd een maagzweer aanzienlijk minder vaak geconstateerd en reflux 
oesophagitis juist vaker (hoofdstuk 2).  
Etiologie: Vaak wordt gedacht dat stemmingsstoornissen te maken hebben met het ontstaan van 
onverklaarbare buikklachten. In het verleden is inderdaad aangetoond dat patiënten met 
functionele dyspepsie meer angst- en depressieklachten hebben dan gezonde controles. Een 
vergelijking tussen twee grote groepen, waarvan de patiënten in de ene groep wel een organische 
oorzaak voor hun symptomen hadden en de andere niet, toonde geen verschil in angst- of 
depressie (hoofdstuk 3). Serotonine is een belangrijke neurotransmitter die zowel stemming als 
maag- darmmotiliteit en sensibiliteit beïnvloedt en vaak geassocieerd wordt met het ontstaan van 
functionele buikklachten. Het effect van een functioneel polymorphisme in het gen dat codeert 
voor het heropname eiwit dat de activiteit van serotonine beëindigd, is voorheen onderzocht in 
patiënten met het prikkelbare darmsyndroom. Een meta-analyse van deze uiteenlopende 
resultaten toonde aan dat er geen associatie is (hoofdstuk 4). 
Diagnose: Er zijn verschillende pogingen gedaan om eigenschappen te definiëren van patiënten die 
een organische aandoening hebben voor hun klachten. Huisartsen hanteren een aantal criteria om 
patiënten voor een gastroscopie te verwijzen. In dit proefschrift wordt aangetoond dat deze 
redenen om een patiënt te verwijzen geen toegevoegde waarde hebben op het vinden van een 
organische aandoening boven wat verwacht mag worden op basis van de prevalentie van die 
aandoening (hoofdstuk 5). Daarnaast werd de waarde van alexithymia, een karaktereigenschap die 
mensen die moeite hebben met het onderscheiden van emoties en lichamelijke gewaarwordingen 
identificeert, onderzocht. De hypothese was dat mensen die hier meer moeite mee hebben 
gevoeliger zijn voor het ontwikkelen van functionele buikklachten, maar er kon geen associatie 
worden aangetoond (hoofdstuk 6). Ten slotte werd de waarde van symptomen geanalyseerd. 
Omdat patiënten zich met symptomen bij een arts presenteren, is het de meest voor de hand 
liggende manier om patiënten in te delen. Er zijn verschillende classificatie systemen opgesteld, 
waarvan de Rome criteria de meest bekende zijn. Het bleek dat symptomen niet bruikbaar zijn 
om patiënten te classificeren en dat kleine aanpassingen in definities bepalen of patiënten wel of 
geen functionele dyspepsie hebben (hoofdstuk 7). 
Behandeling: Vaak wordt in patiënten met functionele dyspeptische klachten een gastroscopie 
gedaan omdat het uitsluiten van een organische aandoening zowel de arts als de patiënt 
geruststelt. Gebruikmakend van angst- en depressiescores als maatstaf voor psychisch 
welbevinden, werd echter aangetoond dat een negatieve gastroscopie de patiënt niet geruststelt 
(hoofdstuk 8). Van het autonome zenuwstelsel wordt vaak gedacht dat het een belangrijke rol 
speelt bij het ontstaan van functionele buikklachten. Antidepressiva beïnvloeden dit systeem op 
verschillende plekken en studies in patiënten met het prikkelbare darmsyndroom lieten een 
overwegend positief effect zien op klachten. In een gerandomiseerd placebo gecontroleerd 
onderzoek naar het effect van venlafaxine in patiënten met functionele dyspepsie kon echter geen 
enkel effect worden aangetoond (hoofdstuk 9). 
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Het promotietraject wordt geacht een beproeving te zijn waarbij de promovendus een 
aanzienlijke persoonlijke ontwikkeling doormaakt om zich daarna met recht een ‘Philosophiae 
Doctor’ te mogen noemen. Nou, een beproeving was het. Soms. Als het regende, een analyse niet 
klopte, of als er vreemde monsters verzameld moesten worden. Veel vaker was het leuk en 
leerzaam; en dat is te danken aan de personen die ik in die tijd om mij heen had.  
 
Ik ben mij er erg van bewust dat de volgende regels met het meeste enthousiasme gelezen 
worden. Ik ga ervan uit dat als je nu gretig op zoek gaat naar je eigen naam, je een directe of 
indirecte bijdrage aan dit proefschrift hebt geleverd. Ik wil je dan ook bijzonder bedanken voor je 
nuttige advies, goede raad, gezelligheid, lekkere koffie of andere onmisbaarheid! 
 
Vier jaar geleden kwam ik in ‘de Kelder’ terecht; zwaar onder de indruk van het 
ziekenhuisbestaan en zo groen als gras op het gebied van onderzoek. Daar trof ik een bende 
pioniers aan die onderzoek deden naar alles wat los en vast zit aan het maag-darmstelsel. Aan het 
hoofd van deze onderzoeksclub stonden professor Jan Jansen en Robert Laheij.  
Jan, op de een of andere manier kreeg je het voor elkaar om in de heksenketel van het ziekenhuis 
een soort luwte te creëren in de vorm van de Kelder. De bewoners van de Kelder hadden 
toegang tot het ziekenhuis, maar het ziekenhuis niet tot de Kelder. Gelukkig maakte je zelf graag 
gebruik van je eigen luwte: ik heb heel veel van je geleerd en ik heb bijzonder veel waardering 
voor de persoonlijke manier waarop we hebben samengewerkt.  
Van Robert leerde ik dat creativiteit ook heel anders kan dan met kurk. Het was inspirerend om 
te merken hoe je op verrassende ideeën en oplossingen kan komen door buiten de kaders te 
denken. Je was voor mij een goede baas: ‘we gooien je in het diepe en laten je even flink 
spartelen’. Ik ben nooit helemaal verzopen.  
De Kelder was de Kelder niet geweest zonder Leo en Martijn, mijn paranymfomaniacs. Jullie 
hebben me onderzoeks-wise gemaakt en fungeerden vaak als frustratie-afreageer-klaagmuur. Als 
ik terugdenk aan Leo’s heftige monologen, Martijn’s warme bad, en al die briljante (maar soms 
teveel uitgemolken) grappen, moet ik weer hardop lachen!  
Dan waren er nog de DIAMOND ladies, Corrine, Gerdine en Suhreta, die altijd wel voor wat 
opschudding zorgden. En Marcel, die uit het raam starend de meest briljante theorieën bedacht. 
Op het nippertje kwam Serena erbij: gezellig! 
 
Sally, Julian en Ties hebben tijdens hun stages een grote bijdrage geleverd aan verschillende van 
de beschreven studies: ik wil jullie alledrie heel erg bedanken voor al het werk, ik hoop dat jullie 
net zoveel hebben geleerd van mij als ik van jullie. 
 
Buiten de Kelder waren er nog een heleboel mensen in het ziekenhuis die betrokken waren bij 
een of meerdere studies. Alle mensen van het lab, met name Annie, Rene en Hennie bijzonder 
bedankt voor jullie raad en daad. De dames van het secretariaat MDL en natuurlijk ook van de 
endoscopie afdeling: tussen alle normale werkzaamheden door was er altijd tijd om me even te 
helpen of iets op te lossen. Wim en Zuster Karin van de Functieafdeling: niet alleen was er altijd 
wel ruimte om patiënten te ontvangen op jullie afdeling, er was ook altijd ruimte voor een praatje. 
Ten slotte waren er buiten het ziekenhuis nog een aantal mensen, zoals Ben Witteman, Sven van 
den Hazel, Nives Apparicio en Wink de Boer. Jullie droegen de broodnodige patiënten aan.  
 
Bedankt Adriaan Tan, co-promotoren van dit proefschrift. Je stelde je afdeling beschikbaar voor 
mijn jacht op deelnemers aan SEREIN en je was altijd bereid mee te denken over oplossingen en 
nieuwe projecten. 
 
Geen enkel project kan succesvol afgerond worden zonder de bijdrage van personen die daar op 
geen enkele manier bij betrokken zijn. Karin, Kim, Karen, Maartje, Nanette, Elbrich, Serena 
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(nogmaals), Sanne, Claire en Madelon: bedankt voor alle goede en minder goede adviezen, de 
borrels, de huilbuien (van jullie dan), de lachstuipen, de kritische commentaren, de serieuze en 
onzin gesprekken, de koffies, de vakanties, de steun, de uitjes. Kortom: for being there! 
 
En natuurlijk Hein. Je hebt het staartje van dit project meegemaakt, maar het was wel een 
belangrijk en vooral roerig staartje! ‘.. En wat zal ik nu eens gaan doen?’ was de centrale vraag die 
ons allebei bezighield. We hebben samen al de meest goede en slechte plannen bedacht, maar 
ach, beter een plan dan geen plan. Ik ben benieuwd wat we allemaal nog gaan bedenken en waar 
het ons nog gaat brengen. Ik heb er in ieder geval zin in! 
 
Jannis en Loes, jullie wil ik bijzonder bedanken voor jullie enthousiasme voor elk nieuw idee, 
jullie ongezouten kritieken en het vermogen mijzelf beter te laten voelen over bepaalde 
eigenschappen omdat het blijkbaar erfelijk is…  ik ben trots op jullie! 
En last but not least: papa en mama... ik kan niet beschrijven hoe fijn het is alles te kunnen doen 
en uitproberen met zo’n sterk vangnet achter je. In de afgelopen jaren zijn de vele functies van 
een keuken ten volste benut en de eettafel deed afwisselend dienst als ontwerptafel voor de meest 
wilde plannen, behandeltafel als de situatie even een relativerende analyse behoefde, maar ook als 
stamtafel waaraan gewoon een beetje gezeverd kan worden. Ik zeg het niet zo vaak, eigenlijk 
nooit, maar jullie zijn THE BEST! 
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